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Background: Previous evidence has demonstrated ethnic differences in the relationship between 
body fat distribution and metabolic risk between black and white women. However, the reasons 
for these differences are not known and may be explained in part by differences in sex hormones. 
The overall aim of this thesis was therefore to i) examine ethnic-specific associations between 
body fat and its distribution and cardio-metabolic outcomes (study 1) and ii) examine the 
associations between sex hormones and subcutaneous adipose tissue (SAT) expression of 
oestrogen receptors (ERα and ERβ) and aromatase (CYP19A), and body fat distribution and 
insulin resistance (IR) among black and white women (study 2).  
Methods: Study 1: In 288 black and 197 white premenopausal women, dual-energy X-ray 
absorptiometry (DXA) and computed tomography (CT) derived measures of body fat 
distribution and cardio-metabolic factors including IR (HOMAIR) and lipid levels were 
measured. Study 2: In a subsample consisting of 13 normal-weight and 15 obese black and 15 
normal-weight and 12 obese white women,  HOMAIR and SI (frequently sampled intravenous 
glucose tolerance test) and ERα, ERβ and CYP19A gene expression were measured in 
abdominal and gluteal SAT. 
Results: Study 1: Compared to white women, black women had less central and greater lower-
body fat, but had similar IR and lower serum lipid concentrations. Despite these differences, the 
associations between body fat distribution and measures of IR, as well as TG and HDL-C 
concentrations were similar in black and white women. Notably, central and peripheral fat 
deposition was independently associated with IR in both the black and white women, and with 
TG in the black women. In contrast, the associations between body composition and fasting 
plasma glucose, TC and LDL-C concentrations differed between black and white women. 
Fasting glucose concentrations were associated with centralisation of body fat in black but not 
white women, whereas TC and LDL-C concentrations were associated with centralisation of 
body fat in white but not black women. In addition to body fat distribution, MVPA was 
associated with IR in the white women, and contraception use was associated with lipid levels in 
the black and white women. Study 2: CYP19A expression was positively associated with 
increased adiposity in black and white women in all three depots. Gluteal ERα was significantly 
higher and ERβ was significantly lower in the black compared to the white women, irrespective 
ix 
 
of BMI. Gluteal ERα was negatively associated with trunk fat mass (FM) and HOMAIR in the 
black women only. Gluteal ERα was significantly lower in obese white compared to normal-
weight white women. Additionally oestradiol (E2) levels were lower in obese compared to 
normal-weight white women, but did not differ by ethnicity.  
Conclusion: Our results indicate that it is important in both black and white populations, to 
decrease centralisation of body fat. Modifiable risk factors such as MVPA and contraception use 
should be used as therapeutic targets to prevent and manage CVD. Additionally, oestrogen receptors 






Non-communicable diseases (NCD‟s) such as Type 2 diabetes (T2D) and cardiovascular 
diseases (CVD) are a large global problem (1), and in 2000, were the second highest cause of 
death in South Africa (SA) (37%) (2). Obesity is known to be major risk factor for CVD and 
T2D (3-6). According to the South African National Health and Nutrition Examination Survey 
(SANHANES), the prevalence of overweight and obesity in SA women is high compared to SA 
men (24.8 and 39.2% compared to 20.1% and 10.6% for males and females, respectively) (7). 
Black SA women had the highest prevalence of overweight and obesity compared to the other 
racial groups, with 64.8% being overweight and obese and 39.9% being obese (figure 1) (7).  
 
Figure 1. Prevalence of overweight and obesity in South African women (SANHANES) (7). White 
women were excluded due to small sample size. 
The reason for the higher prevalence of obesity in African women is not known, but the 
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and socio-economic factors may also contribute to the higher prevalence of obesity in black 
women (8-12). For example, in the black community an overweight body type symbolizes 
happiness beauty and being healthy. Another factor such as diet may contribute to higher 
prevalence of obesity in African women. Studies have demonstrated a general trend for increased 
fat intake and decreased carbohydrate intake in black SA women which may contribute to higher 
prevalence of obesity. Further, studies have shown that inactivity in black women from the North 
West was the strongest predictor of obesity and that physical activity in the highest tertile group 
was negatively associated with obesity. However, an in-depth discussion of these factors is 
beyond the scope of this thesis (8-12).  
1.2 Body fat distribution and risk 
Obesity is characterised by insulin resistance (IR) in association with increased insulin to an oral 
glucose load, and a high rate of free fatty acid (FFA) turnover/unit lean body mass (12). Further, 
obesity is associated with dyslipidaemia characterised by higher triglycerides (TG), total 
cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) and lower high-density 
lipoprotein cholesterol (HDL-C) (13 and 14). 
The distribution, rather than the total amount of body fat may be a greater predictor of CVD and 
T2D risk factors such as IR and dyslipidaemia (15-17). There has been growing evidence 
indicating that not all fat stores contribute equally to CVD and T2D risk factors (18).  Numerous 
studies have explored the relationships between central deposition of adipose tissue and CVD 
risk factors among women.  Abdominal obesity, in particular visceral adipose tissue (VAT), is 
strongly associated with dyslipidaemia, IR, coronary heart disease (CHD), and T2D (19-23). 
Several studies using different methodologies to measure abdominal obesity have confirmed the 
notion that “android obesity” or male-type upper-body obesity is a high-risk form of obesity (24-
26). For example, waist circumference (WC), as a measure of central fat mass (FM), has been 
shown to be associated with increased T2D, glucose levels, IR and a poorer lipid profile, 
independent of hip circumference (HC), in European and Australian men and women (27 and 
28). Further, studies conducted only in sub-Saharan/SA black men and women demonstrated that 
an increasing WC was associated with IR and higher lipid levels (29 and 30). Additionally in 
rural African communities, cut-off WC points for predicting metabolic syndrome (MS) factors 
for women was >82cm for women (31 and 32).  Using dual-energy X-ray absorptiometry (DXA) 
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as a measure of body fat distribution, studies conducted in European men and women have 
demonstrated that trunk FM independent of leg FM (33) is associated with post-load glucose and 
IR, as well as with higher TG and lower HDL-C concentrations (33-35). In American white 
women only, trunk FM as measured by DXA was associated with an unfavourable lipid profile 
independent of leg FM (36). Studies in the United States of America (USA) showed that within 
the abdominal region, obese individuals with an increase in VAT accumulation tend to have 
dyslipidaemia and IR. For example, in the multi-ethnic Dallas Heart Study, VAT was shown to 
be associated with homeostasis model of IR (HOMAIR) and dyslipidaemia, whereas 
subcutaneous adipose tissue (SAT) demonstrated a more benign phenotype, showing no 
independent association with dyslipidaemia and IR (37). Further, the Framingham Heart Study 
conducted in men and women demonstrated that although VAT and SAT were correlated with 
metabolic risk factors, VAT was a stronger correlate of metabolic risk compared to SAT. In this 
study it was shown that VAT had a higher odds ratio for MS compared to SAT in women and 
men (4.7 vs. 3.0, and 4.2 vs. 2.5, P<0.001 respectively) (20), suggesting that VAT is a stronger 
predictor of CVD risk than SAT.  
In contrast to central fat accumulation, recent studies have shown that gluteo-femoral fat 
accumulation, described as “gynoid obesity” or lower-body obesity, which is commonly found in 
premenopausal women, is not a major risk for CVD and related mortality (24, 38 and 39). For 
example, HC, as a measure of lower-body fat was associated with lower T2D glucose levels, IR 
and a more favourable lipid profile independent of WC in European and Australian men and 
women and in Portuguese overweight and obese women, HC was associated with reduced fasting 
insulin independent of WC (27, 28 and 40). Using DXA derived measures, in American white 
women, leg FM was associated with a favourable lipid profile independent of trunk FM (36). 
Similarly, in a group of European men and women and postmenopausal (ethnicity not stated) 
women, DXA-derived measures of leg FM were independently of trunk FM (33 and 41) 
associated with a favourable lipid profile, reduced post load glucose concentration and IR (34 
and 35). The role of arm FM on metabolic risk requires further exploration due to contradictory 
findings. The study conducted by Sanchez et al (2013), found no associations with arm FM (35), 
whereas in a group of white, pre- and postmenopausal women, a reduction in arm FM was 
associated with an increase in TC concentrations (36). This is in agreement with Okura et al 
(2004) who demonstrated that in obese and overweight women (ethnicity not stated), arm FM 
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was associated with reductions in LDL-C concentrations (42). Further a study conducted in 
Korean men and women demonstrated that appendicular fat (arm FM and leg FM) had a negative 
association with metabolic risk (26). 
Taken together, these studies suggest that the region where fat is accumulated might have 
differential effects on cardio-metabolic risk. Compared to central FM, lower-body fat is more 
protective against MS (35).  
1.2.1 Ethnic-specific associations between body fat distribution and metabolic risk 
Ethnic differences in overall adiposity/body mass index (BMI) and body fat distribution and the 
association with cardio-metabolic risk factors in black and white women from USA/Europe and 
SA separately, are described in Table 1.  
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Table 1: Summary of select studies that have examined differences in body fat and its distribution and the associations with cardio-metabolic risk 
factors in black and white women. 
  Reference Subject Age (years) 
Overall 





  43 B vs. W 45-65 and 18-30 B>W         
        B & W:         
        + Insulin         
        + Glucose         
        + Lipids         
        W:         
        + TG         
  44 B vs. W 45-64 B>W         
        B & W:         
        + Lipids         
  45 B vs. W 005-14 B>W         
        W:         
        + TG         
  46 and 47 B vs. W 46 vs. 47 B>W B=W B>W     
          B & W: W:     
          + IR + IR     
          + Lipids       
  48 B vs. W 37 vs. 41 B=W B<W B=W     
  56 B vs. W   B=W B<W B:     
          IR: B>W + IR     
          B & W:       
          + IR       
  77 B vs. W 54 B>W     WHR (anthro)   
              B=W   
              B & W:   
              + IR   
  78 B & W 21-46 B=W     B<W (CT) B=W (DXA) 
              B & W: B & W: 
              + IR - IR 
              + Lipids - Lipids 
  79 B & W 18-65 B>W     B=W (DXA) B>W (DXA) 
              B & W: B & W: 
















              + Lipids - Lipids 
  80 B vs. W 16-33 B>W     B=W (DXA)   
              W:   
              + Lipids   
  81 B & W 70-79 B>W       B>W (CT) 
                B & W: 
                - Glucose 
                - Lipids 
  49 and 50 B vs. W 18-45 B=W B<W B>W     
          W: B & W:     
          + IR + IR     
  51 B vs. W 45 vs. 42 B=W B<W B=W     
  53, 54 and 55 B vs. W   B=W B<W B=W     
          IR: B>W       
          Lipids: B<W       
  76 B vs. W   B<W     WC (anthro)   
              B<W   
              MS   
              B<W   
  82 B vs. W 18-45 B=W       B>W (CT) 
                B: 
                + IR 












In summary, for the most part, for the same or higher BMI/body fat, the association between 
obesity and insulin, glucose concentrations and an atherogenic lipid profile were similar in 
African American and white women (43 and 44). In contrast, both Folsom et al (1991) and 
Frierichs et al (1978) showed obesity was less strongly related to TG concentrations in the black 
compared to the white women (43 and 45).  
Further, studies in the USA have shown that compared to Caucasian women, African American 
women have less VAT and more SAT, largely due to greater superficial rather than deep SAT 
(DSAT) (46-48). Similarly, studies in SA comparing obese black and white women have shown 
that when matched for BMI, black women present with lower VAT and more SAT, in particular 
greater superficial SAT (SSAT), than white women (49-52). Further, the studies in USA and SA 
showed that despite having less VAT, black women were more IR compared to their white 
counterparts (53-56).  Moreover, these studies showed that IR was more closely associated with 
VAT than SAT in the white women (46, 49, 56 and 57), whereas in black women, IR was more 
closely associated with SAT, and more particularly DSAT, rather than with VAT (49).  
Commensurate with lower VAT in black compared to white women, black women have lower 
TC, LDL-C and TG concentrations compared to white women (55 and 58). Studies in SA have 
demonstrated that black women also have the same or lower HDL-C concentrations compared to 
white women (51, 59 and 60), whereas studies in the USA demonstrated higher HDL-C 
concentrations in black compared to their white counterparts (61 and 62). Black SA women may 
be protected against CHD because of this more favourable serum lipid profiles which in turn 
may be attributed to their body fat distribution (62). However, it is not known whether their 
lower HDL-C concentrations may infer greater risk. Notably, in white women lipid levels, 
namely TG and TG/HDL-C concentrations correlate with IR, which is not the case in black 
women, despite their higher level of IR (59, 61 and 63-66). Rather, other studies have 
demonstrated that the major determinants of lipid levels in the black women were use of 
hormonal contraceptives, socioeconomic status, and other lifestyle factors such as diet, alcohol 
consumption, and smoking (59 and 67-70). It is important to note that lipid levels in the black 
SA population are increasing, largely due to rapid urbanisation (71). 
Studies conducted in SA and USA using anthropometric and DXA-derived measures of body fat 
distribution demonstrated that central FM was lower in black compared to white women (72-75). 
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A study conducted in SA by Kalk et al (2008), demonstrated that black diabetic men had a lower 
prevalence of MS compared to white men, which could be explained partly by their smaller WC 
(76). Indeed, waist-hip ratio (WHR) was associated with increased IR in both African American 
and white women (77). In a random sample of premenopausal white and African American 
women, DXA-derived central FM was positively related to fasting insulin, IR, LDL-C, TC/HDL-
C, and TG concentrations and negatively associated with HDL-C concentrations (78 and 79). In 
contrast, a study in USA demonstrated that the association between central FM and serum lipid 
levels was more strongly significant in white compared to black women (80). 
In contrast to central FM, studies in the USA and Europe have shown that computed tomography 
(CT)- and DXA-derived measures of lower-body fat (i.e. thigh fat, relative leg fat) were higher in 
black compared to white women (75 and 81). Similarly, studies in SA using DXA demonstrated 
that black women have greater peripheral fat (arm FM and leg FM) mass compared to white 
women (72 and 82). Studies in the Europe demonstrated that in both black and white women, 
thigh fat was associated with glucose and lipid levels in black and white women independent of 
abdominal fat (81). In addition, in a random sample of premenopausal white and African 
American women, leg FM was similarly related to reduced fasting insulin, IR, LDL-C, TC/HDL-
C, and TG and higher HDL-C concentrations (78 and 79). In contrast, a small SA study 
demonstrated that gluteal fat in the black women was associated with increased IR (82). 
To date, the SA studies that have examined the ethnic-specific associations between body 
composition and cardio-metabolic risk among black and white women have only used 
anthropometric-derived measures of body composition, or specifically examined the associations 
between VAT and SAT, measured using CT. Studies in America/Europe have demonstrated 
ethnic-specific associations with body composition and metabolic risk using DXA- or CT 
derived measures of body composition. A major objective of this thesis was therefore to 
determine if differences in body fat distribution (using both DXA- and CT) between black and 
white women were associated with their cardio-metabolic risk profile (i.e. both IR and lipid 
levels), and if central vs. peripheral fat were independently associated with metabolic risk in 
black and white SA women. This has not been conducted in black and white South African 




1.2.2 Mechanisms underlying the association between body fat distribution and 
metabolic risk 
The mechanisms underlying the effects of body fat distribution on cardio-metabolic risk are still 
not known. Possible mechanisms are discussed in brief below.  
1.2.2.1 FFA 
It is known that FFA play an important role in the development of CVD. Whole body FFA 
release is increased in upper body obesity under both post-absorptive (83 and 84) and post-
prandial conditions (85 and 86), compared to non-obese or lower-body obesity, due to higher 
rates of lipolysis in the abdominal vs. peripheral depots (83 and 85-87). The adipocytes in 
abdominal sites are more resistant to anti-lipolytic effects of insulin than in peripheral sites (96 
and 97). The explanation for this is not clear, but some have argued that it may relate to the 
larger size of the abdominal or visceral adipocytes compared to the peripheral adipocytes (88-
90).  Indeed, reduction of fat cell size through weight loss during diet and exercise, improves 
insulin regulation of lipolysis (91). Notably, VAT releases FFA directly into the hepatic portal 
system, altering hepatic metabolism of lipids and insulin signalling. However, due to its sheer 
volume, SAT may contribute more FFA to the system (92). However, it has been proposed that 
excess FFA release is associated with ectopic fat deposition in organs such as the pancreas, liver 
and muscle and contribute to and worsen IR and T2D (93 and 94).  
Due to the direct link of VAT to the liver through the portal vein, the delivery of FA in the portal 
circulation may cause reduced hepatic insulin clearance (95-97). In hepatocytes, FFA inhibits 
insulin binding due to a reduction in insulin receptors. This is followed by a decrease in insulin 
degradation and the action of insulin is also inhibited (95, 98 and 99). Increased FFA in the 
portal circulation may increase glucose synthesis by preventing the normal insulin mediated 
suppression of glucose output by the liver, and dyslipidaemia (100). 
One function of very low-density lipoprotein (VLDL) is to export excess energy from the liver, 
in the form of TG (101). VLDL synthesis is regulated by TG which in turn is dependent on FFA 
levels. Portal FFA may therefore regulate the synthesis of VLDL and apolipoprotein B (ApoB) 
(a protein backbone for VLDL and LDL) (95 and 102). This therefore suggests that increased 
FFA levels results in increased synthesis and therefore increased circulating levels of VLDL, 
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ApoB and LDL (95, 102 and 103).  An overproduction of VLDL is associated with 
hypertriglyceridaemia (103 and 104). Hypertriglyceridaemia is associated with increased TG, 
low concentrations of HDL-C and high concentrations of LDL-C (105 and 106). In addition to 
less VAT, studies have demonstrated that black women have less hepatic fat compared to white 
women (107 and 108). This might therefore explain their lower lipid levels compared to white 
women. Another study conducted in SA demonstrated that white women had higher late 
postprandial FFA levels compared to black women. This therefore suggests that higher VAT 
levels may be the reason for higher FFA levels and in turn dyslipidaemia demonstrated in white 
women (109). 
Increased accumulation of fat in skeletal muscle may be due to increased availability and uptake 
of FA or reduction in FA oxidation (110). This process is usually demonstrated as elevated levels 
of FFA, TG and increase intracellular accumulation of lipid intermediates such as TG, 
diacylglycerols (DAG), ceramides and long-chain fatty acyl-coenzyme A (LC-CoA) (111). 
Compared to white women, African American women have higher post absorptive skeletal 
muscle lipoprotein lipase (LPL) activity and are metabolically inflexible (112). Further, in vitro 
studies have shown FA oxidation in skeletal muscle and mitochondrial function is lower in 
premenopausal African American compared to white women (113 and 114). Ethnic differences 
in muscle oxidation may potentially be related to muscle fibre composition. Studies have shown 
that compared to white women, African American women have less type I oxidative fibres and 
more type IIb glycolytic fibres (115). Increase in FA oxidation by-products, such as DAG, 
ceramides, and long chain acyl-CoA, rather than intramuscular adipose tissue (IMAT) alone, is 
associated with the development of IR (116). 
Most recently it has been demonstrated that impairment of insulin secretion from chronic 
pancreatic exposure to FFA results in hyperglycaemia due to loss of glucose sensing by β-cells 
(117-119). Hyperglycaemia is associated with accumulation of TG 10-fold higher than normal in 
the pancreas, as hyperglycaemia inhibits fat oxidation (118 and 120). Therefore hyperglycaemia 
and increased FFA may act synonymously in causing damage to the B-cell due to inhibition of 
detoxifying lipid accumulation (121). 
Compared to upper-body fat stores, the release of FFA from lower-body fat stores is reduced, 
and lower-body fat has been suggested to act as a metabolic sink, storing excess FFA when there 
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is an energy surplus (83, 85-87 and 122). Adipocytes in the gluteo-femoral region are less 
sensitive to lipolytic stimuli and more sensitive to anti-lipolytic stimuli than adipocytes in the 
abdominal region (123 and 124). LPL activity is high in the gluteo-femoral region and may 
therefore favour the catabolism of TG rich lipoproteins, the clearance of TG from diet and their 
storage in adipose tissue (93, 122, 125-128). A study conducted in a small sample of black and 
white women from America demonstrated that LPL activity was higher in the black population 
compared to their white counterparts (62). This may therefore suggest that black women may be 
more efficient at clearing hypertriglyceridaemia compared to white women (43). Lower-body fat 
may protect against ectopic fat deposition and therefore protect against IR, impaired insulin 
secretion and risk for CVD and T2D (81). 
1.2.2.2 Adipokines 
Adipose tissue can be regarded as an endocrine organ secreting factors such as adipokines (129). 
With obesity, adipocyte size increases which results in increase in macrophage infiltration and 
increase release of cytokines and decrease release of the insulin-sensitizing adipokine, 
adiponectin (130-136). Differences in the contribution of abdominal and gluteo-femoral fat to 
metabolic risk may be due to depot-specific differences in the secretion of adipokines. For 
example, tumour necrosis factor alpha (TNFα) is secreted by macrophages within adipocytes and 
may play a role as a mediator for IR in obesity (137-140). This cytokine is also present in high 
concentrations in abdominal obesity (141). Studies have demonstrated that TNFα interferes with 
insulin signalling and reduces expression of insulin-sensitive glucose transporter type 4 protein 
and translocation (142). This occurs by TNFα inhibiting IR tyrosine kinase in tissues responsible 
for insulin stimulated glucose uptake (i.e. muscle and fat) (143). Mutagenesis studies have shown 
that IR tyrosine kinase is very important for the biological activities of insulin (144). TNFα has 
been shown to increase the release of other cytokines such as interleukin 6 (IL-6) (145). IL-6 is 
important in whole-body energy homeostasis and inflammation regulation (140). In vitro and in 
vivo studies have demonstrated that IL-6 is capable of suppressing LPL activity, resulting in 
hypertriglyceridaemia, IR and impaired insulin secretion (140). Studies conducted in black and 
white women have demonstrated that TNFα expression were higher in gluteo-femoral and 
abdominal adipose tissue (AAT) depots of black compared to white women, and this was 
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particularly in the gluteo-femoral depot (146). There was no difference in the expression of IL-6 
between the white and black women (146 and 147).  
In contrast to AAT, gluteo-femoral adipose tissue has been shown to have a more beneficial 
adipokine profile (93). Population studies have demonstrated that leptin, a key regulator in 
energy intake and expenditure, and adiponectin levels were positively associated with gluteo-
femoral fat (93). Leptin is involved in both the signal transducer and activator of transcription 3 
(STAT3) pathway and insulin receptor substrate phosphoinositide 3-kinase (PI3K) pathway 
(148). STAT3 is important in mediating food intake and liver glucose production (148). Studies 
show that leptin levels are positively associated with metabolic risk (146), while obesity and IR 
are associated with low adiponectin levels (131, 132, 149 and 150). Adiponectin improves IR by 
increasing energy expenditure and FA oxidation by activation of AMP-activated protein kinase 
(AMPK) and by increasing the expression of peroxisome proliferator-activated receptor gamma 
(PPARα) target genes (151). Studies examining ethnic differences in adipokines and their 
association with metabolic risk are contradictory. A study conducted in black and white SA 
women demonstrated that adiponectin expression was lower in gluteo-femoral fat compared to 
abdominal fat (146), and reported no ethnic differences in the expression of adiponectin among 
the black and white women. In contrast, leptin gene expression was higher in abdominal fat of 
black compared to white women and was higher in gluteal fat compared to abdominal fat depot. 
In both black and white women, leptin expression was positively correlated with IR, while 
adiponectin expression was negatively correlated with IR irrespective of depot (146). Although 
black women were more IR and had a higher gluteal SAT inflammatory profile than white 
women, SAT inflammatory gene expression was not significantly associated with IR and only 
accounted for 20% of the variance. In contrast, in white women, abdominal SAT inflammatory 
gene expression was significantly associated with IR accounting for 56% of the variance (146). 
In contrast, Smith et al (2010) found no difference in abdominal expression of leptin between 
white and African American women matched for BMI and IR (152). 
Additionally, Evans et al (2011) demonstrated that although black women had lower central 
obesity, serum adiponectin and leptin levels did not differ by ethnicity. However, adiponectin 
levels were higher and leptin levels were lower in normal-weight compared to obese women 
(146). In contrast, African American women had higher serum leptin concentrations compared to 
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white women (153). Ferris et al (2005) demonstrated that in a group of black and white SA 
women, serum adiponectin levels were lower in black compared to white women and correlated 
inversely with HOMAIR in the white women (154). Additionally, in African American and 
Caucasian women, serum leptin levels were found to be associated with greater central FM in 
Caucasian women only (155). In a group of African American men and women, serum leptin 
was positively correlated with VAT and HOMAIR. In contrast, serum adiponectin negatively 
correlated with VAT and HOMAIR (156).  
This differences in findings may be due difficulty in determining the true effects of 
adipocytokines with traditional molecular biology methods, as adipocytokines may act in a 
paracrine, endocrine, and autocrine manner. We have provided evidence for the association 
between body fat distribution and metabolic risk and demonstrated possible mechanisms 
responsible for this among black and white women. However, intervention and longitudinal 
studies are required for a better understanding of the mechanisms underlying IR and higher 
prevalence of T2D in African. 
1.2.2.3 Other  
There are several other mechanisms that may influence body fat distribution and its association 
with metabolic risk. Some of these factors include behavioural factors such as physical activity, 
diet and demographic factors (12). Other factors include disturbances in glucocorticoid hormones 
as well as sex hormones. 
1.3 Determinants of body fat distribution 
1.3.1 Gender and body composition  
Clear sexual dimorphisms exist in body fat accumulation and body fat distribution, primarily 
linked to reproductive function. Women generally store more fat and are more likely to be obese 
than males (7). In addition, females have more SAT and greater fat stores in the lower-body 





1.3.2 Menopause, obesity and body fat distribution 
The role of sex hormones in body composition is clearly evident during the menopausal 
transition (157). Menopause is associated with an increase in VAT and a decrease in peripheral 
SAT. For example a cross-sectional study conducted by Gambaccianni and colleagues measuring 
fat distribution using DXA in premenopausal, perimenopausal and postmenopausal women 
demonstrated that both perimenopausal and postmenopausal women showed increase in total and 
central adipose tissue compared to premenopausal women (158). These results suggest that even 
during the perimenopausal period, increased abdominal fat accumulation can be observed. 
Further, Kotani et al (1994) using CT showed that after menopause, the accumulation of VAT 
with age was accelerated (159). Longitudinal studies (160 and 161), over a 6 year period, showed 
significant increases in WHR in only the women who changed their menopause state. On 
average, women who became postmenopausal experienced increases in WHR two-fold higher 
compared to women who were premenopausal (160).   
This is supported by hormone replacement therapy studies in which menopause-induced re-
distribution of fat to the central depots was prevented by hormone replacement (162-164). 
Studies conducted by den Tonkelaar and colleagues showed that in a large sample of Dutch pre- 
and post-menopausal women, the use of oestrogen was associated with a lower WHR (162 and 
163). A small number of oestrogen users in the longitudinal study conducted by Bjorkelund et al 
(1996) showed that the transition from premenopause to postmenopause resulted in an increase 
in WC and a decrease in HC, and the use of oestrogen replacement resulted in the postponement 
of this (161). However, this was not the case in older postmenopausal women, suggesting that 
during menopause, oestrogens may only delay the accumulation of abdominal fat (161). These 
results therefore suggest that hormone replacement therapy prevents or delays the increase in 
AAT accumulation observed at menopause and highlights the pivotal role that hormones play in 
determining body fat distribution. 
1.3.2.1 Hormonal changes and menopause 
Changes during menopause lead to progressive loss in ovarian function, leading to a reduction in 
sex hormones, oestrogen and progesterone (165 and 166). Oestrogen is synthesized in the 
ovaries. Oestradiol (E2) is synthesized by the aromatization of androstenedione to oestrone, 
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followed by the conversion to E2 (167). Studies have demonstrated that ovariectomy increases 
adipose deposition, increases the accumulation of VAT, disrupts glucose and lipid homeostasis, 
increases the risk for developing cardiovascular diseases and IR, and that oestrogen replacement 
reverses this (168-173). The extent to which the direct effect of oestrogen on adipose tissue is 
responsible for the prevention of fat accumulation is still under investigation. Oestrogen may 
exert effects on several adipokines that are produced by adipocytes (174). Oestrogen levels in 
premenopausal women have been shown to be closely associated with leptin levels (175 and 
176). Additionally in mice, oestrogen has been shown to reduce leptin resistance (177). 
Oestrogen increases leptin sensitivity by controlling the expression of leptin specific receptors 
(176, 178 and 179). In contrast, a recent study conducted by Yeaung et al (2013) in lean and 
obese premenopausal women showed that greater adiposity, measured by BMI, was associated 
with higher E2 and lower progesterone, luteinising-hormone (LH) and follicle stimulating 
hormone (FSH) (180). A recent study conducted by Cassaza et al (2008) on the effect of 
oestrogen on insulin levels in pubertal African American and European American girls 
demonstrated that higher insulin levels were associated with higher E2 levels in the African 
American compared to European American girls (181). Further independent of E2 levels, 
menarche was reached at a younger age in African American girls than white girls. Menarche 
was associated with an accelerated fat deposition in African American but not white American 
girls (181). Further, some studies have demonstrated lower E2 levels in African American 
women than Caucasian women approaching menopause (182), while others found no significant 
racial difference (183).  
In contrast to oestrogen, circulating levels of Sex hormone binding globulin (SHBG), may be 
used as a marker for androgen status and is an indirect measure of testosterone to oestrogen ratio 
(184), and has been shown to be negatively associated with obesity (185). SHBG is a circulating 
steroid binding protein, which binds reversibly and with high affinity to testosterone (184). 
SHBG is an important determinant of testosterone in women and is an index of both free and 
SHBG bound testosterone levels (figure 1) (186). Women with low SHBG have higher free 
testosterone that is biologically active (187). Studies conducted in premenopausal African 
American and Caucasian/European women demonstrated that SHBG was negatively associated 
with IR and obesity (187 and 188). Other studies demonstrated that SHBG was negatively 
correlated to BMI and IR in Caucasian and not African American women (189). As SHBG is 
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produced in the liver, insulin may act directly on the liver to inhibit SHBG synthesis (190). 
Additionally, Patel et al (2009) demonstrated that higher free testosterone was associated with IR 
and CHD in postmenopausal women (191). Other studies conducted in premenopausal women 
demonstrated that testosterone levels were positively correlated with body FM (kg and %) and 
lean mass in women aged 20-25 years (192). These studies therefore suggest that low SHBG, 
may be a phenotype that envisages CVD and its risk factors in black women. However, studies 
have demonstrated that although SHBG was lower and free testosterone was higher in white 
women with greater upper body fat compared to lower-body fat, the levels of SHBG and 
testosterone were not altered with extremes of body fat in the black women (193). A study 
conducted by Yeung et al (2010) in American women demonstrated that although SHBG levels 
were similar in black and white women, body fat and trunk FM as a percentage of FM was 
shown to be negatively associated with SHBG in the white, but not black women. However, WC 
and trunk FM/leg FM was negatively associated with SHBG in both the black and white women 
(194). 
 
Figure 2: Schematic diagram of forms of testosterone and regulation by SHBG in the body. Free 
testosterone is biologically active and SHBG-bound testosterone is biologically inactive. An increase in 
SHBG results in an increase in SHBG bound testosterone and a decrease in bioavailable testosterone. T, 
testosterone; +, increases and -, decreases (186). 
1.4 Oestrogen and its receptors 
The known effects of oestrogen are mediated by ligand activated transcription factors known as 
oestrogen receptors (ER) (195). There are two types of ER‟s, oestrogen receptor alpha (ERα) 
(196) and oestrogen receptor beta (ERβ) (197). ERα is located on chromosome 6 and ERβ is 
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located on chromosome 14, and is homologous to ERα (195 and 198). Studies have 
demonstrated that ERβ inhibits the transcriptional activity of ERα depending on the 
concentration of oestrogens (199). Hall et al (1999) have shown that at a higher concentration of 
oestrogen, both ERα and ERβ had maximal transcription activity; however, the transcriptional 
activity of ERα was greater than ERβ. Increasing ERβ had no effect on the ERα transcriptional 
activity. At lower (sub-saturating) levels of oestrogen, only ERα is active. When ERβ was 
increased, the activity of ERα was suppressed (199). This suggests that the biological response to 
oestrogens is dependent on the relative ratios of ERα and ERβ levels. This suggests that different 
ER‟s are responsible for different functions. 
Studies show that ERα plays an important role in adipose tissue deposition. Studies conducted in 
premenopausal women demonstrated that ERα was reduced with obesity, and increased after 
weight reduction (200).  ERα knockout (ERKO) mice show an increase in adipose deposition, 
VAT, IR and impaired glucose tolerance (201-204) but also show a 8-fold increase in oestrogen 
levels (205), and increased signalling through ERβ could be a factor contributing to obesity of 
ERKO mice. Indeed, Naaz et al (2002) demonstrated that removal of oestrogen/ERβ signalling in 
ovariectomised ERKO mice resulted in a decrease in body weight and IR (206).  
The effects of oestrogen to maintain reduced body fat appear to be mediated by ERα. 
Oestrogen/ERα signalling is critical in maintaining reduced IR and reduced obesity. This 
important role for oestrogen/ERα signalling in maintaining glucose homeostasis is supported by 
evidence obtained from ERβ knockout (BERKO) mice. Studies have demonstrated that BERKO 
mice had either no change or decreased IR and improved glucose tolerance (202, 203 and 207). 
Ludwig et al (2008) showed that ERβ acts through PPARϒ (207), (which is known to regulate 
glucose and lipid metabolism by modulating energy homeostasis in adipose tissue, liver and 
skeletal muscle) by inhibiting ligand mediated PPARϒ-transcriptional activity (208-210). 
PPARϒ was shown to enhance cellular processes involved in lipid accumulation, such as 
adipogenesis. The study also showed that absence of PPARϒ can lead to lipodystrophy and 
eventually IR (211). Studies conducted in black and white women demonstrated that in black 
women, PPARϒ mRNA levels were reduced with obesity (50). Goedecke et al (2011) also 
demonstrated that PPARϒ was down-regulated to a greater extent with obesity in black women 
compared to white women. Decreased expression could be an adaptive process limiting further 
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accumulation of adipose tissue. They also found that PPARϒ mRNA levels were negatively 
associated with IR in black but not white women. Consistently, low PPARϒ activity leads to 
cardiovascular and metabolic pathophysiological consequences such as IR, diabetes and end 
organ damage (208).  
Another possible mechanism for ERKO mice maintaining reduced IR is demonstrated by 
increase in the expression of genes involved in lipid biosynthesis and a decrease in genes 
involved in lipid transport (202). Studies in ERKO mice have found that stearoyl-CoA desaturase 
(SCD1) is increased (202). SCD1 catalyses the synthesis of monounsaturated FA from saturated 
FA. These monounsaturated FA are used as substrates for the synthesis of TG and cholesteryl 
esters (212). Studies conducted in rodents have shown that SCD1 is high in conditions including 
obesity, diabetes and IR (213 and 214). However, a study in mice showed that a decrease in SCD1 
worsens the diabetes in obese mice (215). Other studies conducted in humans have demonstrated 
lower adipose and hepatic SCD1 mRNA expression in obese compared to non-obese subjects 
and is negatively associated with IR (216 and 217).  
ERKO mice also have increased plasma leptin and decreased expression of leptin receptor 
(LEPR) (202). Leptin is a hormone that is known to regulate adipose tissue mass by acting 
through LEPR (218). In other studies, increased plasma leptin levels and a reduction in LEPR 
expression in the hypothalamus and adipose tissue was demonstrated in ovariectomised mice. 
These levels were normalized by oestrogen treatment (219). Ovariectomised mice treated with 
E2 had significant increases in hepatic LEPR mRNA which suggests a direct role of oestrogens 
on the regulation of LEPR (202). It is therefore possible that the SCD1 and LEPR expression 
may be an important mechanism underlying IR in ERKO mice.   
Further evidence supporting the role of oestrogen/ERα signalling in reducing obesity and IR was 
shown by a study conducted in aromatase knockout mice (ARKO) (220). ARKO mice were 
shown to be obese and have a phenotype that is similar to that of ERKO mice (221-223). P450 
aromatase activity in adipose tissue is important in oestrogen production. Aromatase (CYP19A) 
converts androstenedione to oestrone followed by the conversion to E2 (167). In human and 
mice studies, deficiency of CYP19A results in abdominal obesity, glucose intolerance and IR, 
and treatment with E2 decreases IR (221, 223, 224 and 225). CYP19A transcript levels, which 
are highest in the gluteal region, next highest in the thigh and lowest in the abdominal SAT (226 
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and 227), are significantly greater in women with lower-body (gynoid) obesity than upper 
obesity (228). Studies conducted in Caucasian men and women (premenopausal) demonstrated 
that generalized obesity, characterised by BMI, was associated with an increase in CYP19A 
mRNA levels (229). In contrast, CYP19A mRNA levels in omental adipose tissue were inversely 
associated with BMI. However, this study was conducted in a smaller sample (230). The former 
study also suggested that an increase in ER‟s due to an increase in SAT CYP19A binding to 
androgen receptors may favour peripheral fat distribution. Another study demonstrated that a 
gain of function mutation in CYP19A was associated with female body fat distribution in a male 
patient (231). These studies therefore suggest that an increased CYP19A in SAT may generate 
more oestrogen ligands and consume more androgen ligands which may favour peripheral fat 
deposition in obese women. 
ER gene expression levels may also be mediated by methylation in a variety of tissues. However, 
this has only been conducted extensively in breast tissue in which studies demonstrated that 
normal breast tissue and ER positive cell lines lack methylation. In contrast, ER negative breast 
cancer cell lines display extensive methylation due to an increase in DNA methyltransferase1 
(232). Hormonal and growth factors may also modulate the level of ER‟s in order to regulate the 
growth of various tissues. ER transcription is important in cellular and growth potential as 
signals affect the growth and metabolism of oestrogen responsive tissues (232).  
The studies above provide evidence for the influence of sex hormones and their receptors in 
changes of body fat distribution and IR. Therefore, observed differences in body fat distribution 
and IR between black and white women may be attributed to differences in sex hormones. There 
have been a few studies that have determined the association with circulating sex hormones E2 
and SHBG and body fat distribution and IR in African American and European women. No 
studies of which we are aware have compared the difference in associations of ER‟s and body fat 
distribution and IR between black and white SA women. However, there has only been one other 
study that investigated regional differences in ERα mRNA expression (233). This study was 
conducted in premenopausal women but reported no difference in ERα expression between 
gluteal and abdominal SAT. Other studies conducted measured protein expression and found 




1.5 Literature conclusions 
The prevalence of overweight and obesity among black SA women is high. In addition, black 
women are more IR than white women, but have more peripheral fat and less VAT. This is 
surprising as VAT is known to be the main culprit that contributes to IR. However, the lower 
VAT and greater lower-body fat distribution may explain their lower prevalence of 
dyslipidaemia. The reasons for ethnic differences in body fat distribution are not known, 
however, ethnic differences in sex hormones may explain this. More specifically an increase in 
oestrogen and its receptors and decrease in testosterone and increase in SHBG may explain 
higher gluteal and lower abdominal fat in black women. We set out to determine ethnic specific 
associations between sex hormones and body fat distribution and IR. There have been no studies 
that have examined this in SA black and white women and therefore we are in a unique position 
to examine this in a group of women matched for BMI but in whom their body fat distribution 
and cardio-metabolic risk factors differs. 
 
1.6 Aims and objectives 
The overall aims of this thesis were to: 
1) Examine ethnic-specific associations between body composition and cardio-
metabolic risk factors; 
2) Examine the association between sex hormones and body fat distribution and 
IR among the black and white women.  
Therefore the aims will be addressed in 2 chapters 
Study1: In a convenient sample of black and white premenopausal SA women, to: 
1) Compare body fat distribution, IR and lipid levels;  
2) Determine the associations between body fat distribution, IR and serum lipid levels;  
3) Determine whether these associations differ by ethnicity.  




1) Measure the gene expression of ER‟s and CYP19A in SSAT, DSAT and gluteal 
adipose tissue. 
2) Measure circulating sex hormone concentrations 
3) Examine associations between ER‟s and, CYP19A gene expression, and circulating 




Associations between body fat distribution, insulin resistance and dyslipidaemia in 
black and white South African women 
2.1 Introduction 
Most recent studies show that NCD‟s account for majority of deaths globally (65.5%) (235), and 
that 80% of the deaths attributed to NCD‟s each year are in low-middle income countries (236). 
In 2000, NCD‟s such as CVD and T2D were known to be the second highest cause of death in 
SA (2). Obesity is known to be a major risk factor for CVD and T2D (3-6). The prevalence of 
obesity in SA women is high, particularly in black women (7). However, fat distribution rather 
than the amount of body fat has been shown to be a greater predictor of CVD and T2D risk 
factors such as IR and dyslipidaemia (15-17). There has been growing evidence indicating that 
not all fat stores contribute equally to CVD and T2D risk factors (18).  
Studies in predominantly white populations have shown that central FM (measured as trunk fat 
on the DXA scan or WC) (27, 28, 33-35 and 36), and more specifically VAT (20 and 37), is 
positively associated with IR and dyslipidaemia. Conversely, lower-body SAT (gluteo-femoral) 
(27, 28, 33-35, 36 and 40) has been shown to be negatively associated with these cardio-
metabolic risk factors. Some (27, 33 and 36), but not all of these studies have demonstrated that 
central and lower-body fat have independent effects on metabolic risk.  
However, the relationship between fat distribution and IR appears to be altered by ethnicity. 
Studies in the USA and SA have shown that compared to white women, black women have less 
VAT and higher gluteo-femoral FM, but are more IR (46-56, 72, 75, 81 and 82). Lower VAT in 
the black women may however explain their lower lipid levels compared to white women (62). 
Notably, studies in both USA and SA have shown that despite lower VAT, black women have 
higher abdominal SAT than their white counterparts, which associates positively with IR (46, 49, 
56 and 57). However, the SA studies have only been performed in small samples of women 
(n=10-15) and only focused on abdominal fat distribution.  It is known that peripheral (leg and 
arm) FM is also an important determinant of cardio-metabolic risk.  When examining whole-
body fat distribution using DXA, studies in SA and the USA have shown that black women have 
lower central FM and higher leg FM compared to their white counterparts (72-75, 81 and 82). 
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To date, most studies that have explored ethnic-specific associations between whole-body fat 
distribution and cardio-metabolic risk have been undertaken in the USA or Europe, with no 
studies to our knowledge, examining the independent associations between central and peripheral 
fat distribution and cardio-metabolic risk in SA women.  
Therefore, the aim of this study was to examine differences in whole body fat distribution 
between premenopausal black and white women and the ethnic-specific associations with cardio-
metabolic risk. We also set out to determine if central vs. peripheral fat were independently 
associated with cardio-metabolic risk, and examine which body composition variable was most 
closely associated with cardio-metabolic risk in black and the white women, taking into account 
other lifestyle factors that have been shown to alter body composition, such as physical activity, 
contraception use, smoking and alcohol consumption. 
2.2 Methods and materials 
2.2.1 Subjects: 
The study population consisted of 288 black and 197 white SA women who were recruited by 
advertisement and from local church groups, community centres and universities, as described 
previously (50 and 146). Inclusion criteria were: (i) aged 18-45 years; (ii) no known diseases or 
taking any medication for metabolic disorders; (iii) not currently pregnant, lactating or 
postmenopausal; and (iv) of SA ancestry. This study was approved by the Human Research 
Ethics Committee of the Faculty of Health Science of the University of Cape Town. Procedures 
and risks were explained to participants, all of whom gave written informed consent, prior to 
participation.  
The testing procedures and biochemical analysis have been previously described, but are 
described in brief below (49, 50, 59 and 146).  
2.2.2 Testing procedures:  
2.2.2.1 Demographic and lifestyle questionnaire 
A demographic questionnaire (as employed in other studies (59)), which was based on the DHS 
questionnaire was administered that included measures of socio-economic status, including 
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housing density, family history of T2D and behavioural/lifestyle factors. Contraceptive use was 
recorded, and women were categorized as using hormonal contraception (oral and injection) or 
not. Smoking was recorded and women were categorized as current smokers or not. Alcohol 
consumption in grams/day was also recorded using dietary recall.  
Physical activity energy expenditure was characterised using the Global Physical Activity 
Questionnaire (GPAQ) (237 and 238). Moderate to vigorous physical activity (MVPA) was 
calculated as minutes of physical activity per week. 
2.2.2.2 Body composition 
Anthropometric measurements of participants were taken including height, weight in light 
clothing, WC (at the level of umbilicus) and HC (at the largest gluteal area). BMI was calculated 
as weight (kg) divided by the square of height (m2). Body composition (fat and fat-free mass) 
was measured using DXA (Discovery-W, Software version 4.40; Hologic). Fat mass index 
(FMI) was calculated as total body fat (kg)/height (m2). DXA-derived measures of body fat 
distribution included 1) trunk FM 2) arm FM 3) leg FM 4) android FM and 5) gynoid FM. Trunk 
FM included the region between the neck (line below the bottom of the jaw) and waist (line 
above the iliac crest) cuts with the lateral boundaries positioned to achieve separation of the 
upper arm and trunk at the glenoid fossa, and the inclusion of vertical lines on either side of the 
spine were positioned to exclude the spine. The arms included the region below the line through 
the glenoid fossa. Vertical lines extending downward from the waist cut were positioned to 
separate thigh from hands, and oblique lines were positioned to pass through the femoral neck 
and join the central vertical line between the legs, in order to isolate the legs (239). For android 
FM, the sub-region box was positioned so that that lower border was above the iliac crest and the 
upper border at the lower level of the ribs (excluding the bones). The lateral border was 
positioned so that all soft tissue was included. For the gynoid FM, the sub-region box was 
positioned so that the upper border passed through the most superior points of the inner pelvis. 
The lateral border was positioned so that all soft tissue was included (240). A CT scan (Toshiba 
X-press Helical Scanner; Toshiba Tokyo, Japan) at the level of the L4-L5 vertebrae was taken to 





2.2.3 Blood sampling and biochemical analysis: 
After an overnight fast (10-12hrs) a blood sample was drawn from the antecubital vein, for the 
subsequent determination of plasma glucose, and serum insulin, HDL-C, LDL-C, TC and TG 
levels. Plasma glucose concentrations were determined using the glucose oxidase method (YSI 
2300 STAT PLUS; YSI life sciences, Yellow springs, OH). Serum insulin concentrations were 
determined by immunochemiluminometric assays using the ADVIA Centaur (Bayer diagnostics, 
Tarrytown, NJ). Blood lipids were measured using the Roche modular Autoanalyser (Roche 
Diagnostics GmbH, Sandhofler Strasse 116, D-68305, Mannheim, Germany). Enzymatic 
colourimetric assays were used to analyse TC, TG, LDL-C and HDL-C concentrations. LDL-C 
was calculated using the Friedewald formula (241). 
2.2.3.1 IR 
HOMAIR was calculated from fasting glucose and insulin levels (242). 
2.2.4 Statistical analysis: 
Results were analysed using Statistica version 10 (Statsoft Inc., Tulsa, Oklahoma, USA). Results 
are presented as median and inter-quartile range (IQR). All variables were normalized by log 
transformation, where required. Ethnic differences in body composition, IR, and lipid levels were 
determined using one-way ANCOVA, adjusting for age. Pearson chi-squared was used to 
determine differences in categorical variables between the black and white women. Partial 
correlations were used to determine the associations between the various body fat distribution 
variables and cardio-metabolic outcomes in the black and white women, adjusting for age and 
FMI. FMI was chosen as the covariate because it takes into account both the total body fat and 
the height of an individual (which differs significantly between black and white).  
Multiple regression analysis was used to determine the independent associations between body 
fat distribution and IR and serum lipid levels, adjusting for age and FMI. In addition the effect of 
ethnicity on these relationships was tested by including ethnicity x body fat distribution 
interaction term in the model.  
Backward stepwise regression was used to determine the model that accounted for most of the 
variance for each cardio-metabolic outcome. In each model, trunk FM was used as the measure 
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of central fat and leg FM was used as the measure of lower-body fat due to their stronger 
associations with cardio-metabolic outcomes (Table 5). Other variables included into the model 




Table 2: Subject characteristics of black and white women 
  Black White P-value  
Age (years) 26 (22-33) 32 (24-39) <0.01 
MVPA (mins/week) 335 (90-855) 240 (120-480) 0.01 
Alcohol consumption (g) 0 (0-2.8) 6.1 (0.5-14.7) 0.95 
    Contraception use (% (n)) 32 (281) 31.1 (195) 0.74 
  Oral 6.3 (18)  26 (51) <0.01 
  Injection 25.7 (74) 5.1 (10) <0.01 
Smoke (% (n)) 10.1 (279) 17 (195) 0.04 
Values presented as median and interquartile range (IQR) or %(n). MVPA, moderate-vigorous physical activity. 
Table 3: Body composition and body fat distribution of black and white women. 
    Black    White P-Value 
  N Median (IQR) N Median (IQR) Adjusted for age 
Body composition 
    Height (m) 288 1.60 (1.56-1.64) 197 1.67 (1.60-1.70) <0.001 
Weight (kg) 288 80.4 (60.9-96.2) 197 73.9 (62-94.1) 0.02 
BMI (kg/m2) 288 31.7 (23.6 -37.2) 197 26.6 (22.4-33.2) <0.001 
Fat (kg) 288 33.7 (19.4-44.3) 197 26.7 (17.1-40.3) <0.001 
Fat (%) 288 42.1 (32.7-46.9) 197 36.5 (28.9-43.9) <0.001 
FMI (kg/m2) 288 13.3 (7.6-17) 197 9.9 (6.4-14.5) <0.001 
Body fat distribution       
WC (cm) 288 94.8 (77.3-108.6) 197 88 (78-101.5) <0.001 
Trunk FM (kg) 288 14.1 (7.4-20.6) 197 12.2 (7.4-20.3) 0.01 
Trunk FM (%FM) 288 42.1 (36.7-46.7) 197 45.5 (40.7-49.7) <0.001 
Leg FM (kg) 288 13.7 (9.3-18.01) 197 10.7 (7.5-15.9) <0.001 
Leg FM (%FM) 288 44.3 (39.5-49.4) 197 41.4 (37.5-45.7) <0.001 
Trunk FM/Leg FM 288 0.95 (0.74-1.2) 197 1.1 (0.90-1.3) <0.001 
Arm FM (kg) 288 3.8 (1.9-4.9) 197 2.9 (1.8-4.6) <0.001 
Arm FM (%) 288 10.7 (9.3-12.3) 197 10.8 (9.7-11.9) 0.9 
Android (kg) 288 2.5 (1.1-3.8) 197 2.02 (1.02-3.5) 0.001 
Android (%FM) 288 0.07 (0.06-0.09) 197 0.07 (0.06-0.09) 0.6 
Gynoid (kg) 288 6.1 (4.1-8.0) 197 5.2 (3.7-7.5) <0.001 
Gynoid (%FM) 288 0.19 (0.17-0.21) 197 0.20 (0.18-0.22) <0.001 
Android/Gynoid 288 0.38 (0.27-0.48) 197 0.38 (0.28-0.46) 0.09 
VAT (cm2) 222 71 (47-102) 153 80 (60-124) 0.04 
SAT (cm2) 220 442 (212-577) 150 297 (169-460) <0.001 
VAT/SAT 220 0.20 (0.14-0.27) 150 0.31 (0.23-0.42) <0.001 
Values presented as median and interquartile range (IQR). P values for one way ANCOVA adjusting for age. BMI, body 
mass index; FMI, fat mass index; WC, waist circumference; FM, fat mass; VAT, visceral adipose tissue; SAT, 
subcutaneous adipose tissue. 
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Table 4: Cardio-metabolic risk factors of black and white women. 
    Black   White P-value    






age Adjusted for age and FMI 
Glucose (mmol/L) 280 4.5 (4.2-4.9) 196 4.7 (4.4-4.9) 0.08 <0.001 
Insulin (mU/L) 287 9.8 (5.6-16.6) 197 6.9 (4.6-10.8) <0.001 0.27 
HOMAIR 279 2.1 (1.1-3.4) 196 1.5 (0.96-2.2) <0.001 0.59 
TC (mmol/L) 274 3.9 (3.3-4.5) 197 4.7 (4.1-5.3) <0.001 <0.001 
TG (mmol/L) 274 0.70 (0.50-1.0) 197 0.90 (0.60-1.2) <0.001 <0.001 
HDL-C (mmol/L) 273 1.2 (1.0-1.6) 197 1.6 (1.4-1.9) <0.001 <0.001 
LDL-C (mmol/L) 273 2.2 (1.7-2.8) 197 2.6 (2.1-3.3) <0.001 <0.001 
Values presented as median and interquartile range (IQR). P values for one way ANCOVA adjusting for age and age and 
FMI. HOMAIR, homeostasis model for insulin resistance; TC, total cholesterol; TG, triglycerides; HDL-C, high-density 
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.  
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2.3.1 Subject characteristics 
Subject characteristics are summarized in Table 2. Black women were younger than white 
women, and consequently, all subsequent analysis was adjusted for age. Black women had 
higher levels of MVPA compared to white women, and more white women smoked, whereas 
alcohol consumption did not differ between groups. There was no significant difference in the 
proportion of women who used contraceptives, but more white women used oral contraceptives, 
while more black women used injectable contraceptives.  
Ethnic differences in body composition and fat distribution are summarized in Table 3. Black 
women were significantly shorter, heavier, had a higher BMI and greater FM (absolute and %) 
compared to white women. Black women had greater absolute measures of trunk, leg and arm 
FM compared to white women.  However, as a percentage of total body FM, black women had 
less trunk FM and greater leg FM. Accordingly, trunk FM/leg FM ratio was greater in white than 
black women. As a percentage of total body FM, there was no significant difference in arm FM 
between black and white women. In addition, black women had greater absolute measures of 
android and gynoid FM than white women, however, as a percentage of total FM there was no 
significant difference between groups. Black women had less abdominal VAT and more SAT 
and a lower VAT/SAT ratio compared to white women.  
Cardio-metabolic risk factors for black and white women are summarized in Table 4. Although 
there were no ethnic differences in fasting plasma glucose concentrations, black women had 
higher fasting insulin concentrations and HOMA-IR than white women. After adjusting for 
differences in age and FMI, glucose concentration were significantly lower in the black 
compared to the white women, but the differences in fasting serum insulin concentrations and 
HOMAIR were no longer significant. Black women had significantly lower TC, TG, HDL-C and 




Table 5: Correlations between body fatness and its distribution and cardio-metabolic risk factors in black and white women and the combined sample 









FMI (kg/m2) B 0.26∆ 0.53∆ 0.54∆ 0.23∆ 0.035 -0.31∆ 0.15* 
 
W 0.23∆ 0.61∆ 0.61∆ 0.35∆ 0.26∆ -0.39∆ 0.36∆ 
 All 0.25∆ 0.59∆ 0.60∆ 0.30∆ 0.13∆$ -0.34∆ 0.25∆$ 
Trunk FM (kg) B 0.34∆ 0.30∆ 0.34∆ 0.30∆ -0.060 -0.23∆ -0.039 
 W 0.069 0.29
∆ 0.29∆ 0.099 0.043 -0.18∆ 0.12 
  All 1.04∆$ 1.16∆ 1.23∆ 0.92∆ -0.09$ -0.87∆ 0.09$ 
Android (kg) B 0.23∆ 0.24∆ 0.26∆ 0.24∆ -0.10 -0.20∆ -0.083 
 W 0.041 0.33
∆ 0.32∆ 0.14 0.072 -0.21∆ 0.15* 
  All 0.59∆$ 0.87∆ 0.90∆ 0.71∆ -0.13$ -0.71∆ 0.03$ 
VAT (cm2) B 0.12 0.24∆ 0.27∆ 0.078 -0.034 -0.099 0.0011 
 W -0.039 0.21
∆ 0.19* 0.21* 0.10 -0.25∆ 0.17* 
  All 0.10$ 0.33∆ 0.33∆ 0.20∆ -0.04$ -0.28∆ 0.05$ 
SAT (cm2) B 0.094 -0.023 0.019 -0.11 -0.039 0.15* -0.071 
 W -0.25
∆ -0.0002 -0.017 -0.016 0.15 0.16 0.079 
  All 0.13$ 0.18 0.20 -0.06 -0.20$ -0.06 -0.19$ 
Leg FM (kg) B -0.16∆ -0.33∆ -0.34∆ -0.23∆ -0.011 0.15* -0.015 
 W -0.12 -0.25
∆ -0.26∆ -0.16* -0.097 0.19∆ -0.15* 
  All -0.38∆ -0.67∆ -0.69∆ -0.52∆ -0.09 0.39∆ -0.15 
Gynoid (kg) B -0.084 -0.28∆ -0.27∆ -0.19∆ -0.0003 0.12* -0.013 
 W -0.055 -0.16
* -0.16* -0.15* -0.17* 0.14 -0.19∆ 
  All -0.21 -0.56∆ -0.55∆ -0.49∆ -0.17 0.34∆ -0.23 
Trunk FM/Leg FM B 0.30∆ 0.39∆ 0.42∆ 0.34∆ -0.027 -0.24∆ -0.012 
 W 0.12 0.34
∆ 0.34∆ 0.17* 0.092 -0.23∆ 0.17* 
  All 0.28∆$ 0.42∆ 0.43∆ 0.32∆ 0.03$ -0.28∆ 0.08$ 
Android/Gynoid B 0.22∆ 0.34∆ 0.35∆ 0.28∆ -0.07 -0.22∆ -0.06 
 W 0.06 0.34
∆ 0.35∆ 0.20∆ 0.16* -0.25∆ 0.24∆ 
  All 0.23∆$ 0.45∆ 0.45∆ 0.38∆ 0.03$ -0.33∆ 0.09$ 
VAT/SAT B 0.043 0.21∆ 0.21∆ 0.14* 0.0010 -0.19∆ 0.06 
 W 0.13 0.22
∆ 0.23∆ 0.22∆ 0.0069 -0.37∆ 0.12 
  All 0.07 0.22∆ 0.22∆ 0.20∆ 0.01 -0.27∆ 0.10 
Values are presented as partial correlation coefficients adjusted for age and FMI (except for FMI). ∆. p<0.01 and *.p<0.05. “All” values are presented as beta 
coefficients adjusted for age, FMI and ethnicity. $, ethnic x body composition interaction. FMI, fat mass index; VAT, visceral adipose tissue; SAT, subcutaneous 
adipose tissue; FM, fat mass; HOMAIR, homeostasis model of insulin resistance; TG, triglycerides; TC, total cholesterol; HDL-C, high-density lipoprotein 
cholesterol; LDL-C, low-density lipoprotein cholesterol. 
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2.3.2 Associations between body fatness and its distribution and cardio-metabolic risk 
factors. 
Table 5 shows the partial correlations (adjusted for age and FMI) between body fatness and its 
distribution and cardio-metabolic risk factors for the black and white women individually and 
combined. In summary, when adjusted for age, greater total body fat, as defined by FMI, was 
positively associated with plasma glucose concentrations, measures of IR (fasting insulin and 
HOMA-IR), TG and LDL-C concentrations and negatively associated with HDL-C 
concentrations in both black and white women. FMI was positively associated with TC in white 
women only.  
In black and white women, increased central FM and reduced lower-body fat correlated with 
measures of IR (fasting insulin and HOMAIR). In black women only, greater central fat, 
characterised by trunk FM, android FM, trunk FM/leg FM and android/gynoid, and lower leg 
FM were associated with increased fasting plasma glucose concentrations. Notably these 
associations with glucose concentrations and central FM were significantly different between 
black and white women. In white women only, increased abdominal SAT was associated with 
reduced fasting glucose concentrations, and this association differed significantly between black 
and white women.  
In both black and white women, reduced lower-body FM characterised by leg FM and gynoid 
FM and increased trunk FM/leg FM and android/gynoid was associated with TG concentrations. 
In the black women, higher trunk FM and android FM, and in the white women higher VAT was 
associated with TG concentrations. In addition, in both the black and white women, central fat, 
characterised by trunk FM, android FM, trunk FM/leg FM and android/gynoid, was associated 
with reduced HDL-C concentrations. In contrast higher leg FM was associated with increased 
HDL-C concentrations in both the black and white women. In white women only, 
android/gynoid was positively associated with TC concentrations, while gynoid FM was 
negatively associated with TC concentrations. Notably the former relationship differed 
significantly between black and white women.  Increased android FM, trunk FM/leg FM, 
android/gynoid and VAT were associated with increased LDL-C concentrations. These 
associations differed significantly in black and white women. In contrast, reduced lower-body fat 
32 
 
was associated with increased LDL-C concentrations in white, but not black women. There were 
no associations between arm FM and any metabolic risk factor in the black and white women. 
The confounding effects of various lifestyle factors, including contraceptive use, smoking, 
physical activity and alcohol consumption on metabolic risk are shown in supplementary tables 9 
and 10. In summary, in black women, IR was higher and HDL-C concentrations were lower in 
women on contraception than not. Despite few black women consuming alcohol, consumption 
was positively associated with serum HDL-C concentrations in black women. In white women, 
TC, TG and HDL-C concentrations were higher in women on contraception than not, while 
lower MVPA was associated with higher fasting insulin concentrations and HOMAIR. 
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Table 6: Multivariate analysis for black and white women 
Black       White       
Glucose (mmol/L) 
       Variable B P 
 
Variable B P 
 FMI (kg/m2) -1.11 <0.01 
 
Age (years) 0.18 0.01 
 Trunk FM (kg) 1.47 <0.01 
 
FMI (kg/m2) 0.24 0.00 
   R=0.45 R2=0.21 P<0.01   R=0.34 R2=0.12 P<0.01 
Insulin (mU/L) 
       Variable B P 
 
Variable B P 
 Age (years) -0.33 <0.01 
 
Age (years) -0.25 0.00 
 Trunk FM (kg) 1.09 <0.01 
 
Trunk FM (kg) 1.02 0.00 
 Leg FM (kg) -0.53 <0.01 
 
Leg FM (kg) -0.37 0.00 
 Contraception 0.11 <0.01 
  
   
  R=0.64 R2=0.40 P<0.01   R=0.67 R2=0.45 P<0.01 
HOMAIR 
       Variable B P 
 
Variable B P 
 Age (years) -0.29 <0.01 
 
Age (years) -0.21 0.00 
 Trunk FM (kg) 1.14 <0.01 
 
Trunk FM (kg) 1.03 0.00 
 Leg FM (kg) -0.57 <0.01 
 
Leg FM (kg) -0.38 0.00 
 Contraception 0.11 0.02 
  
   
  R=0.65 R2=0.42 P<0.01   R=0.67 R2=0.45 P<0.01 
TG (mmol/L)        Variable B P 
 
Variable B P 
 Age (years) 0.12 0.04 
 
FMI (kg/m2) 0.90 0.00 
 Trunk FM (kg) 0.84 0.00 
 
Leg FM (kg) -0.51 0.00 
 Leg FM (kg) -0.59 0.00 
 
Contraception 0.26 0.00 
   R=0.48 R2=0.23 P<0.01   R=0.49 R2=0.24 P<0.01 
HDL-C (mmol/L) 
       Variable B P 
 
Variable B P 
 Age (years) 0.20 0.07 
 
VAT (cm2) -0.45 0.00 
 FMI (kg/m2) -1.2 <0.00 
 
Contraception 0.18 0.01 
 Leg FM (kg) 0.77 0.01 
  
   
Contraception  -0.23 0.02 
     Alcohol consumption 0.23 0.02 
       R=0.51 R2=0.26 <0.01   R=0.51 R2=0.26 P<0.01 
TC (mmol/L)       
    Variable B P 
 
Variable B P 
 Age (years) 0.22 0.0021 
 
Age 0.22 0.00 
 FMI (kg/m2) 0.38 0.025 
 
FMI (kg/m2) 0.29 0.00 
 SAT (cm2) -0.36 0.029 
 
Contraception 0.29 0.00 
   R=0.30 R2=0.10 P<0.01   R=0.44 R2=0.19 P<0.01 
LDL-C (mmol/L)       
    Variable B P 
 
Variable B P 
 Age (years) 0.19 0.0071 
 
Age 0.16 0.02 
 FMI (kg/m2) 0.46 0.0073 
 
Trunk FM (kg) 0.38 0.00 
 SAT (cm2) -0.33 0.049 
  
   
  R=0.33 R2=0.11 P<0.01  R=0.46 R2=0.21 P<0.01 
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2.3.3 Multivariate analysis 
In separate models for black and white women, we then used backward stepwise regression to 
determine the factors that accounted for the greatest variance in the cardio-metabolic risk factors 
including the following variables in the initial model: Age, FMI, trunk FM and leg FM. Based on 
the results relating to the covariates described above, we also included these covariates 
(contraception use and alcohol) into the appropriate models. We then repeated the regression 
analyses including VAT and SAT in the models.  
In black women, FMI and trunk FM accounted for 21% of the variance in fasting glucose 
concentrations, whereas in white women age and FMI contributed significantly to the model, 
accounting for only 12% of the variance. In both black and white women, trunk FM and leg FM 
were independently associated with fasting serum insulin concentrations and HOMA-IR, and 
together with age, and in the case of black women, contraceptive use, accounted for 40-45% of 
the variance in the models. The addition of VAT and SAT to the models did not contribute 
independently or significantly to the models for fasting plasma glucose and measures of IR in the 
black and white women 
For the black women, trunk FM and leg FM were independently associated with TG, whereas 
only FMI and leg FM, as well as contraceptive use associated with TG in the white women.  The 
addition of VAT and SAT did not contribute significantly to the model in the black and white 
women. In the black women, HDL-C concentrations were independently associated with age, 
FMI, leg FM, contraceptive use and alcohol consumption, whereas in white women, only VAT 
and contraceptive use contributed to the model. Notably, the associations between HDL-C 
concentrations and contraceptive use were opposite in the black and white women, showing a 
negative association in black women, and a positive association in white women. The model that 
explained the greatest variance in TC and LDL-C concentrations in the black women, included 
age, FMI and abdominal SAT, the latter being negatively associated with TC and LDL-C 
concentrations. This contrasts to the findings for white women, where age, FMI, contraceptive 
use accounted for the greatest variance in TC concentrations, and age and trunk FM contributed 




The main findings of this study were that compared to white women, black women had less 
central and greater lower-body fat, but had similar IR and lower serum lipid concentrations. 
Despite these differences, the associations between body fat distribution and measures of IR, as 
well as TG and HDL-C concentrations were similar in black and white women. The novel 
finding of this study was that central and peripheral fat deposition was independently associated 
with IR in both the black and white women, and with TG in the black women. In contrast, fasting 
glucose concentrations were associated with centralisation of body fat in black but not white 
women, whereas TC and LDL-C concentrations were associated with centralisation of body fat 
in white but not black women.   
Black women had greater total body fat compared to their white counterparts, which is in 
accordance to the recent SANHANES in which the prevalence of obesity in SA black women is 
higher compared to other ethnic groups (7). This study also showed that, as a percentage of total 
body FM, black women had lower central fat and higher lower-body fat compared to the white 
women, which is in agreement with other SA studies that have used DXA to quantify body fat 
distribution (72 and 82), as well as studies from the USA and Europe (73-75 and 81). Further, 
within the abdominal depot, this study showed that black women had less VAT and more SAT 
compared to white women, which is commensurate with both SA and American studies (46-52).  
Lower central, and to a lesser extent, greater peripheral FM, in the black women associated with 
their lower fasting glucose concentrations compared to white women, suggesting that 
accumulation of central FM may play a vital role in determining fasting plasma glucose 
concentrations, and hence the development of T2D in the black women. In contrast to the 
findings for fasting plasma glucose, fasting insulin levels and HOMAIR were not significantly 
different between black and white women, despite the differences in body fat distribution. 
Indeed, numerous studies have shown that compared to white women, black women have a 
higher prevalence of IR and T2D for the same BMI or WC (54 and 56). These results are 
surprising given that greater central and reduced peripheral FM were similarly associated with 
higher fasting insulin and HOMAIR in the black and white women, a finding supported by 
similar studies in the USA (77 and 79). These findings suggest that other factors, in addition to 
body fat distribution are important determinants of IR in black women.  
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Another important finding of this study was that central and peripheral FM were independently 
associated with fasting insulin and HOMAIR in both the black and white women. To our 
knowledge, this is the first study to demonstrate independent associations among black and white 
SA women, a finding that has been demonstrated in mostly white men and women (27, 33 and 
36). Differences in the contribution of abdominal and gluteo-femoral fat to IR may be due to 
phenotypic differences in adipose tissue depots. Studies in predominantly white populations have 
shown, for example, that cytokines, such as TNFα and IL-6 are expressed in high concentrations 
in abdominal obesity, and have been suggested to play a role as mediators of MS in obesity (137-
140 and 145). In contrast, gluteo-femoral adipose tissue has been shown to have a more 
beneficial adipokine profile, secreting factors such as leptin (93). Indeed, studies from our 
laboratory have shown that in white women, inflammatory gene expression, especially in the 
abdominal depot, was significantly associated with higher IR (146). However, SAT 
inflammatory gene expression was not significantly associated with IR in the black women, 
despite their being more IR and having a higher SAT inflammatory profile, especially in the 
gluteal depot, than white women. This finding may suggest that factors other than inflammation 
may contribute to higher IR in the black women.  
Lower-body fat has been suggested to act as a metabolic sink, storing excess FFA when there is 
an energy surplus (83, 85-87 and 122), due to its lower lipolytic activity and higher LPL activity 
compared to upper body fat stores (93, 122 and 125-128). A study conducted in a small sample 
of black and white women from America, demonstrated that LPL activity was higher in the black 
compared to the white women, possibly explaining their greater lower-body fat deposition (62). 
Lower-body has been suggested to protect against ectopic fat deposition and therefore protect 
against risk for CVD and T2D. However, when the capacity to store excess fat in the periphery is 
exceeded, peripheral fat is no longer protective. A small SA study demonstrated reduced 
adipogenesis and lipogenesis in obese black women, and this was associated with increased IR 
(50). A recent study from our laboratory has shown that with increasing weight gain, black 
women accumulate more central relative to peripheral FM, which was associated with increased 
IR (Chantler et al., in review). These findings imply that the prevention of an increase in weight 
gain is vital for the prevention of metabolic risk in black women and it is important to determine 
the point at which peripheral FM is protective. 
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In addition to body fat distribution, other lifestyle factors also influenced IR, but differed 
between black and white women. In the black women only, contraceptive use, which was 
predominantly injectable contraceptives, was associated with increased IR. Similarly, other 
studies demonstrated that women using injectable contraception had significantly greater insulin 
levels compared to those that were on oral contraception (243). The mechanism by which 
injectable contraception may cause increased insulin levels has yet to be elucidated, but may 
reflect compensation for increased IR, which is associated with increased FA among injectable 
contraceptive users (244). Another mechanism may include reduced clearance, degradation, or 
increased return of insulin to circulation (245). In addition, physical activity was differentially 
associated with IR in the black and white women. There are a number of studies that 
demonstrated that physical activity influences metabolic risk. For example results from the 
Canadian Heart Health Survey showed that participants who engaged in more than 30 minutes of 
vigorous-intensity physical activity were less likely to have MS (246). A study conducted in 
black SA women using objectively measured physical activity demonstrated that light-intensity 
physical activity was only associated with reduced central FM and not cardiometabolic risk 
factors (247). In our study, despite white women having lower MVPA than black women, 
MVPA was associated with IR in white women only. Previous research from our laboratory has 
demonstrated that white women mainly perform leisure activity, typically undertaken at a higher 
intensity, whereas black women mainly perform physical activity for travel, typically undertaken 
at a lower intensity. This may suggest that the intensity of exercise is an important determinant 
of IR.  
HDL-C and TG concentrations are often used as markers for IR (63 and 64). However, studies 
have demonstrated that TG/HDL-C ratio does not predict IR in African American or black SA 
women as it does for white women (59, 61 and 63-66). This study found that despite similar IR, 
HDL-C and TG concentrations were lower in the black compared to the white women, which is 
commensurate with some but not all studies (51, 55 and 58-62). Notably, similar to the findings 
for IR, higher HDL-C and lower TG concentrations were associated with reduced central and 
increased peripheral FM, and these associations were similar in black and white women, a 
finding supported by studies in the USA (79 and 248). The lower HDL-C concentrations of black 
women must therefore be explained by other factors. HDL-C in the black women was associated 
with alcohol consumption, independent of body fat distribution. Alcohol consumption may raise 
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HDL-C concentrations by increasing the transport rate of the major HDL apolipoprotein Apo-I 
and Apo-II (249). Compared with 76% of white women, 34% of black women consumed alcohol 
and this might therefore partly contribute to their lower HDL-C levels. Contraception use was 
another significant determinant of HDL-C in both the black and white women and TG in the 
white women. Notably contraception use was negatively associated with HDL-C in the black 
women and positively associated in the white women, which could be explained by the type of 
contraception used. Studies have demonstrated that women using injectable contraception have 
lower HDL-C and TG concentrations compared to those that were on oral contraception (250). 
This may be due to suppression of hepatic lipase by ethniyl oestradiol (present in oral 
contraception) which slows the transport of HDL-C and increases TG to the liver. Desogesterel, 
the progestin in oral contraception, is less androgenic than first and second generation progestins, 
so does not counteract the oestrogen effect in this contraception (250). This may therefore 
explain, in part, the differing HDL-C concentrations in the black and white women.  
In our study we also demonstrated that independent of body fat, TC and LDL-C concentrations 
were lower in the black compared to the white women, which is in agreement with similar SA 
studies (51, 55 and 58-60). Additionally we demonstrated that increased TC and LDL-C 
concentrations were associated with increased central FM in the white women only. Hosain et al 
(2010) also demonstrated that the association between central FM and lipid levels were stronger 
in the white compared to the black women (80). It is important to note that increased trunk FM 
was significantly associated with increased LDL-C concentrations in the white women, whereas 
in the black women, abdominal SAT area was negatively associated with LDL-C and TC 
concentration, suggesting a protective effect of SAT in the black women. There have been a 
number of studies that have demonstrated that SAT is protective against IR and increased lipid 
levels, more specifically TG in women with higher BMI (251). Additionally lipodystrophic loss 
of SAT results in increased IR and dyslipidaemia (252). In contrast, other studies in women have 
demonstrated loss of abdominal SAT does not produce the same beneficial results as VAT in 
terms of reduced IR and dyslipidaemia (253). This is the first study of which we are aware, that 
has demonstrated a protective effect of abdominal SAT on cardio-metabolic risk in black 
women. A possible mechanism for the protective role of SAT is that it is an alternative depot for 
excess FFA, potentially reducing ectopic fat deposition in VAT and liver, thereby preventing 
lipotoxicity and reducing dyslipidaemia (254).  
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We found no associations between arm FM and any metabolic risk factor in the black and white 
women, a finding supported by a study conducted in only white men and women (35). Other 
studies in obese pre- and postmenopausal women found a reduction in arm FM was associated 
with an increase in TC and LDL-C concentrations after adjusting for total body fat and other 
body fat distribution variables in the study (i.e. Trunk FM, leg FM, SAT) (36 and 42).  In both 
African American and white women, increased arm FM was associated with having 2 or more 
risk factors for MS (254). Although arm FM is regarded as „peripheral fat mass‟, this is from the 
upper-body and therefore may not exhibit the same protective effects as leg FM. Due to 
contradictory findings further exploration is required. 
The strengths of this study include the state-of-the-art measures of body fat distribution, DXA 
and CT, and the examination of ethnic-specific associations between these measures and cardio-
metabolic risk. Possible limitations of the study were the inclusion of a convenient sample of 
women, which is not representative of total population. Black women were more obese that 
white women but this maybe reflective of the population according to SANHANES. The cross-
sectional design of the study limits one to derive conclusions in terms of causality. The number 
of women in which CT scans were conducted was low (76% of total sample) and this may have 
created type II error. Further, we did not measure other lifestyle factors such as diet and this has 
been shown to affect body fat and metabolic risk. More objective measures of physical activity 
using accelerometers should be used as it would give more insight into possible differences in 
non-exercise thermogenesis within these populations and should therefore be conducted in future 
studies. Future studies should also include subjects with a wider age range as metabolic risk 
factors differ with age. 
In conclusion, this study showed that black women had lower central and greater peripheral fat 
compared to white women, which was associated with lower fasting glucose concentrations in 
the black women and higher TC and LDL-C concentrations in the white women. Increased 
central and reduced peripheral FM were independently associated with measures of IR in both 
the black and white women. In addition to body fat distribution, modifiable risk factors were 
identified, including MVPA, which was associated with reduced IR in the white women, and 
contraceptive use, which was associated with IR and lipid levels in the black and white women. 
Intervention studies aimed at reducing centralisation of body fat, increasing physical activity and 
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changing contraceptive use are required to verify these findings to provide evidence-based 




Adipose and circulating sex hormones: Associations with body composition and 
insulin resistance in black and white South African women  
3.1 Introduction 
In chapter 2, we demonstrated that greater central body fat, characterised by increased trunk FM 
and android FM, was associated with increased IR, while leg FM and gynoid FM were 
negatively associated with IR, which is supported by various international studies (27, 28, 33-35 
and 36). Despite this, this thesis also showed that although black women had less VAT and 
central FM, and greater lower-body fat than their white counterparts, they had similar levels of 
IR. Previous studies conducted in SA and the USA have demonstrated that compared to their 
white counterparts, black and African American women were more IR despite their lower VAT 
and greater lower-body fat (53-56). Further, it has been shown that VAT and SAT were similarly 
correlated to IR in white women, however, in black women SAT was more closely correlated 
with IR than VAT (46, 49, 56 and 57).  
The reasons for ethnic differences in the relationship between body fat distribution and IR are 
not known, but could be explained in part by differences in sex hormones. Sex hormones play 
important roles in determining body fat and its distribution, as evidenced by sex-specific 
phenotypes with men displaying a preponderance towards central obesity, while women have 
greater peripheral obesity (7 and 24). Indeed, an increase in oestrogen levels is related to an 
increase in gynoid body fat (162-164). Conversely, studies have demonstrated that circulating 
oestrogen deficiency, experienced at the menopausal transition, is associated with an increase in 
central FM, IR and increased risk for developing CVD, and this is reversed with oestrogen 
replacement (162-164).  
The effects of oestrogens are mediated by ER‟s, ERα and ERβ which are expressed in human 
adipose tissue (195-197). It has been demonstrated that ERα and ERβ have different actions and 
ERβ may even oppose the actions of ERα (199). Studies conducted in ERKO mice demonstrated 
an increase in VAT, IR and impaired glucose tolerance (201-204). The effects of oestrogen to 
maintain reduced body fat appear to be mediated by ERα. Oestrogen/ERα signalling is critical in 
maintaining reduced IR and reduced obesity. This important role for oestrogen/ERα signalling in 
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maintaining glucose homeostasis is supported by evidence obtained from BERKO mice. Studies 
have demonstrated that BERKO mice had either no change or decreased IR and improved 
glucose tolerance (202, 203 and 207). Studies in humans have demonstrated that ERα expression 
is reduced in obese premenopausal women and expression increases after weight reduction 
(200). In contrast, ERβ but not ERα was significantly higher in adipose tissue of postmenopausal 
compared to premenopausal women (255). However, oestrogen production is also dependent on 
CYP19A activity in adipose tissue, which converts androstenedione to oestrone followed by the 
conversion to oestrogen (167). Studies in the USA have shown that CYP19A transcript levels 
were highest in the gluteal region and lowest in abdominal SAT (226 and 227) and were 
significantly greater in women with gynoid-type obesity compared to upper body obesity (228). 
The importance of CYP19A maintaining glucose homeostasis is supported by evidence obtained 
from ARKO mice, which present with glucose intolerance and IR (221-223). ARKO mice were 
also shown to be obese and have a phenotype similar to ERKO mice due to a lack of functional 
CYP19A gene, resulting in decreased oestrogen (221-223). Further, studies conducted in humans 
have shown that a decrease in CYP19A activity resulted in glucose intolerance and IR (223 and 
224).  
In postmenopausal women, increasing androgen levels (e.g. testosterone) are associated with IR 
(191). Other studies conducted in premenopausal women (aged 20-25 years) demonstrated that 
testosterone levels were positively correlated with body FM (kg and %) and lean mass (192) and 
were higher in women with greater central obesity (256). SHBG can be used as an indicator for 
androgen status and is an indirect measure of the testosterone to oestrogen ratio (184). Studies 
have demonstrated that women with high SHBG levels have low free testosterone levels, which 
were associated with reduced obesity and IR (187-189). Studies have demonstrated that although 
SHBG was lower and free testosterone was higher in white women with greater upper body fat 
compared to lower-body fat, the levels of SHBG and testosterone were not altered with extremes 
of body fat in the black women (193). Further, a study conducted by Yeung et al (2010) in 
American women demonstrated that body fat and trunk FM as a percentage of FM, were 
negatively associated with SHBG in white, but not black women (194). 
The studies above provide evidence for differences in sex hormones and their receptors in 
determining body fat distribution and IR. We therefore hypothesized that difference in body fat 
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distribution and IR between black and white women may be associated with differences in sex 
hormones and their receptors. Although there have been a few studies that have examined the 
associations between circulating sex hormones, E2 and SHBG, and body fat distribution and IR 
in African American and white women, no studies of which we are aware of have compared the 
ethnic-specific associations of ER gene expression and body fat distribution and IR between 
black and white women. We are in a unique position to examine this in a group of black and 
white women matched for BMI, but in whom their body fat distribution and cardio-metabolic 
risk factors differ. Therefore in a sample of normal-weight and obese black and white SA 
women, the aim of this study was to examine the associations between sex hormones and body 
fat distribution and IR among black and white women. The objectives were therefore to: 
4) Compare the ethnic differences in expression of ER‟s ERα and ERβ, and CYP19A 
genes in abdominal and gluteal SAT depots; 
5) Compare circulating sex hormone concentrations in the black and white women; 
6) Examine the associations of ERα and ERβ, and CYP19A mRNA levels within each 
depot and circulating sex hormones with body fat distribution and IR in black and 
white women. 
3.2 Methods and materials 
3.2.1 Subjects: 
The study population, a subsample of participants described in the previous chapter, consisted of 
13 normal-weight and 15 obese black and 15 normal-weight and 12 obese white SA women who 
were recruited by advertisement and from local church groups, community centres and 
universities, as described previously (24). Inclusion criteria were: (i) aged 18-45 years; (ii) no 
known diseases or taking any medication for metabolic disorders; (iii) not currently pregnant, 
lactating or postmenopausal; and (iv) of SA ancestry. This study was approved by the Human 
Research Ethics Committee of the Faculty of Health Science of the University of Cape Town. 
Procedures and risks were explained to participants, all of whom gave written informed consents, 




3.2.2 Testing procedures:  
The testing procedures including body composition, IR and fat biopsies have been previously 
described (49, 50, 59 and 146), but are described in brief below.  
3.2.2.1 Demographic and lifestyle questionnaire 
As described in chapter 2, a demographic questionnaire was administered that included measures 
of socio-economic status. Contraceptive use was also recorded and women were categorized as 
using hormonal contraception or not.  
Physical activity energy expenditure was characterised using the GPAQ (237 and 238). Minutes 
of physical activity per week were recorded. 
3.2.2.2 Body composition 
Anthropometric measurements of participants, as described earlier in chapter 2 were taken 
including height, weight, WC and HC. Body composition (fat and fat-free mass) was measured 
using DXA (Discovery-W, Software version 4.40; Hologic). FMI was calculated. DXA-derived 
measures of body fat distribution included 1) trunk FM 2) leg FM 3) android FM and 4) gynoid 
FM. VAT, DSAT and SSAT areas were measured using CT scan (Toshiba X-press Helical 
Scanner; Toshiba Tokyo, Japan) at the level of the L4-L5 vertebrae.  
3.2.2.3 IR 
After an overnight fast, subjects underwent an insulin-modified frequently sampled intravenous 
glucose tolerance test (FSIGT) to quantify IR. Cannulae were inserted into the antecibutal vein 
of each arm. One arm was used for glucose and insulin infusions and the other arm was used for 
blood sampling. Baseline samples were drawn at -15, -5 and -1 minute before the infusion of 
glucose (50% dextrose, 11.4 g/m2 body surface area) over 60 seconds at time 0. At 20 minutes 
human insulin (0.02 U/kg; Actrapid, Novo Nordisk, Sandton, South Africa) was infused over 5 
minutes at a constant rate. Plasma glucose and serum insulin concentrations were measured in 3 
baseline samples and 32 samples drawn over 240 minutes after the commencement of the 
glucose infusion. Glucose and insulin drawn from the FSIGT were used to calculate the insulin 
sensitivity index (S1) using the minimal model of glucose kinetics of Bergman et al (1979) (257). 
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HOMAIR was also calculated from fasting glucose and insulin levels (242). 
3.2.2.4 Fat biopsies: 
After 4h of fasting, fat biopsies were obtained from the abdominal DSAT, SSAT and gluteal 
areas using a mini liposuction technique. A small insertion was made directly above the 
umbilicus after local anaesthesia with Lignocaine hydrochloride (2%, Intramed, Port Elizabeth, 
South Africa). 200-300ml of normal saline with adrenaline (0.1%, Intramed) and Lignocaine 
(0.75%) was infused using an infiltration cannula (Lamis 14 ga × 15cm, Bryon Medical Inc., 
Tucson, AZ, USA). Under ultrasound guidance fat was aspirated from above (SSAT) and below 
(DSAT) the fascia superficialis using an aspiration cannula (Coleman. 12 ga × 15cm, Byron 
Medical Inc.) attached to a 10ml syringe. Gluteal samples were obtained from the upper right 
quadrant using the same procedure. Approximately 2ml of fat was obtained from each site and 
washed three times with saline until no blood was visible. Samples were placed into vials, frozen 
in liquid nitrogen and then stored at -80ºC (146).   
3.2.2.5 Isolation of RNA: 
Total RNA was isolated using the QIAGEN RNeasy system (QIAGEN Ltd., Crawley, UK) The 
yield and purity of the RNA was determined using a spectrophotometer (ND-1000 
spectrophotometer; NanoDrop Technologies, Wilmingtom, DE, USA), and RNA integrity was 
analysed by 1% agarose gel electrophoresis in the presence of SYBRE gold nucleic acid stain 
(Invitrogen Molecular ProbesTM, Oregon, USA). RNA samples were stored at -80°C for 
subsequent analysis.   
3.2.2.6 Real-time quantitative PCR (RT-PCR): 
RT-PCR was performed in triplicate. Reverse transcription of 2µg RNA was performed using 
Taqman RT reagents (High Capacity cDNA Reverse Transcription Kit; Applied Biosystems, 
Foster City, CA, USA) and RNase inhibitor (Applied Biosystems, Foster City, CA, USA)) at a 
final concentration of 1U/ml. mRNA levels of ERα, ERβ, and CYP19A were quantified (relative 
quantification standard curve method) using Taqman universal PCR master mix 2X and Taqman 
gene expression assays (Applied Biosystems, Foster City, CA, USA): ERα (Hs00174860_m1), 
ERβ (Hs00230957_m1/Hs01100353_m1), Aromatase (CYP19A1) (Hs00903413_m1/ 
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Hs00240671_m1), 18S (Hs99999901_s1), RPLPO (Hs99999902_m1), and Cyclophilin (PPIA) 
(Hs04194521_s1). Each sample was analysed in triplicate on a StepOnePlus real-time PCR 
detection system (Applied Biosystems, Foster City, CA, USA). Expression levels were 
calculated using a standard curve. Reference genes were evaluated by running 18S, PPIA and 
RPLPO on the full study cohort and relative levels of expression genes were normalized using 
RPLPO as determined by NormFinder algorithm as the best housekeeping gene (258). 
3.2.3 Biochemical analysis: 
Plasma glucose and serum insulin concentrations were determined as described in chapter 2 (24 
and 146). Circulating levels of hormones E2 (CV: 1.45%), progesterone (CV: 4.34%) and free 
testosterone (CV: 4.04%) were measured using competitive immunoassay (Centaur, direct 
chemiluminescent technology, Siemans South African Health Care Diagnostics, Johannesburg, 
South Africa), FSH (CV: 2.46%) and LH (CV: 2.08%) were measured using two site sandwich 
immunoassay (Centaur, direct chemiluminescent technology, Siemans South African Health 
Care Diagnostics, Johannesburg, South Africa) and SHBG (CV: 2.36%) was measured using 
sandwich immunoassay (Centaur, direct chemiluminescent technology, Siemans South African 
Health Care Diagnostics, Johannesburg, South Africa).  
3.2.4 Statistical analysis: 
Results were analysed using Statistica version 10 (Stat-soft Inc., Tulsa, OK). Results were 
presented as mean ± standard error (SE). The differences in body composition, circulating 
hormonal levels and mRNA levels within each depot between the ethnicity and BMI groups were 
analysed using two-way ANOVA with Fischer LSD post hoc analysis. Partial correlations 
adjusting for age, FMI and contraception were used to test the associations between circulating 
hormones, gene expression, body fat distribution and measures of IR in the black and white 
women separately. Differences in these associations between black and white women were tested 




Table 7: Subject characteristics of normal-weight and obese black and white women 
 
Normal-Weight Obese P-Value  
  N Black N White N Black N White Ethnicity BMI 
Ethnicity X 
BMI 
Age (years) 13 23 ± 0.81# 15 26 ± 0.89# 15 28 ± 1.94#* 12 33 ± 1.99#* 0.008 <0.001 0.31 
Body composition 
          Height (m) 13 1.6 ± 0.02* 15 1.7 ± 0.02* 15 1.6 ± 0.01* 12 1.7 ± 0.01* <0.001 0.60 0.50 
Weight (kg) 13 56.5 ± 1.7#* 15 64.9 ± 1.1#* 15 95.7 ± 2.5# 12 103.7 ± 5.1# 0.002 <0.001 0.28 
BMI (kg/m2) 13 22.7 ± 0.37# 15 22.7 ± 0.39# 15 38.6 ± 0.74# 12 37.4 ± 1.5# 0.36 <0.001 0.41 
Lean (kg)                  13  36.9 ± 1.4#* 15  42.3 ±0.94#*  15   47.9 ± 1.4#* 12   53.04 ±2.3#*  0.004  <0.001 0.42  
Fat (kg) 13 16.9 ±1.1# 15 19.2 ± 1.2# 15 44.6 ± 1.4# 12 47.3 ± 2.9# 0.077 <0.001 0.68 
Fat (%) 13 30.3 ± 1.7# 15 30.03 ± 1.7# 15 47± 0.78# 12 45.9 ± 0.94# 0.89 <0.001 0.87 
FMI (kg/m2) 13 6.8 ± 0.45# 15 6.7 ± 0.42# 15 18.1 ± 0.54# 12 17.1 ± 0.98# 0.74 <0.001 0.87 
Body fat distribution 
          Waist (cm) 13 75.7 ± 1.1# 15 80.1 ± 1.4# 15 115.3 ± 2.6# 12 110.0 ± 4.3# 0.99 <0.001 0.03 
Hip (cm) 13 97.9 ± 1.4# 15 102.3 ± 1.1# 15 126.6 ± 1.6# 12 126.2 ± 4.3# 0.17 <0.001 0.21 
WHR 13 0.77 ± 0.01# 15 0.78 ± 0.01# 15 0.91 ± 0.02# 12 0.87 ± 0.01# 0.17 <0.001 0.08 
Trunk FM 
(kg) 13 6.4 ± 0.53#* 15 8.0 ± 0.59#* 15 22.1 ± 0.76# 12 22.6 ± 1.9# 0.12 <0.001 0.17 
Trunk FM 
(%FM) 13 37.9 ± 1.6#* 15 41.6 ± 1.6#* 15 49.5 ± 0.94# 12 47.2 ± 1.2# 0.89 <0.001 0.02 
Leg FM (kg) 13 7.9 ± 0.59# 15 8.5 ± 0.53# 15 16.4 ± 0.77# 12 18.3 ± 0.86# 0.029 <0.001 0.47 
Leg FM 
(%FM) 13 46.9 ± 1.8# 15 44.4 ± 1.3# 15 36.7 ± 1.07# 12 39.1 ± 1.2# 0.38 <0.001 0.04 
Trunk FM/Leg 
FM 13 0.84 ± 0.07# 15 0.96 ± 0.06# 15 1.3 ± 0.06# 12 1.2 ± 0.07# 0.71 <0.001 0.03 
Gynoid (kg) 13 3.6 ± 0.23#* 15 4.2 ± 0.22#* 15 7.6 ± 0.31# 12 8.5 ± 0.43# 0.003 <0.001 0.95 
Gynoid(%FM) 13 21.5 ± 0.49# 15 22.2 ± 0.69# 15 17.2 ± 0.54# 12 18.2 ± 0.59# 0.11 <0.001 0.51 
VAT (cm2) 12 60 ± 4.8# 15 61 ± 6.2# 13 101 ± 11#* 10 163 ± 18.5#* 0.49 <0.001 0.05 
SAT (cm2) 12 168 ± 15.2# 15 182 ± 15.7# 13 591 ± 25.6# 10 520 ± 30# 0.77 <0.001 0.20 
SSAT (cm2) 12 99 ± 9.3# 15 97 ± 6.6# 13 321 ± 21.9# 10 255 ± 41.2# 0.28 <0.001 0.25 
DSAT (cm2) 12 68 ± 7.40# 15 85 ± 10.1# 13 269 ± 16.2# 10 264 ± 24.7# 0.59 <0.001 0.24 
VAT/SAT 12 0.37 ± 0.02# 15 0.35 ± 0.03 13 0.2± 0.01#* 10 0.32 ± 0.03* 0.31 <0.001 0.001 
Values are expressed as mean ± SE. P-values adjusted for age except for age. #, BMI effect; and *, ethnic effect. BMI, body mass index; FMI, fat mass index; 
WHR, waist-hip ratio; FM, fat mass; SSAT, superficial subcutaneous adipose tissue; DSAT, deep subcutaneous adipose tissue; VAT, visceral adipose tissue.  
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Table 8: IR and circulating sex hormones in black and white normal-weight and obese women. 
  
  
Normal-Weight Obese  P-Value 
  N Black N White N Black N White Ethnicity BMI 
Ethnicity X 
BMI 
Insulin sensitivity                     
Glucose 
(mmol/L) 13 4.5 ± 0.11 15 4.4 ± 0.05# 14 4.6 ± 0.05 12 4.7 ± 0.08# 0.962 0.02 0.24 
Insulin (mU/L) 13 7.9 ± 1.3# 15 5.01 ± 0.61 15 15.6 ± 1.8#* 12 8.1 ± 1.1* 0.003 0.001 0.40 
HOMAIR 13 1.5 ± 0.28# 15 0.97 ± 0.12# 13 2.9 ± 0.39#* 12 1.7 ± 0.25#* 0.041 <0.001 0.66 
SI (x104 
/min/(uU/ml)) 13 2.5 ± 0.49* 14 5.7 ± 0.52#* 14 1.6 ± 0.38* 11 3.5 ± 0.63#* <0.001 0.006 0.45 
Circulating sex hormones                   
E2 (pg/mL) 11 234.3 ± 36.9 14 248.9 ± 26.4# 13 272.3 ± 36.4 11 153.3 ± 38.9# 0.06 0.11 0.01 
TST (nmol/L) 9 0.67 ± 0.13* 15 1.30 ± 0.16#* 13 0.84 ± 0.15* 11 2.46 ± 0.28#* <0.001 0.04 0.16 
SHBG(nmol/L) 11 63.7 ± 9.1# 13 77.9 ± 11.8 14 40.7 ± 6.4# 11 57.1 ± 19.4 0.06 0.04 0.24 
PRGE (ng/mL) 11 8.3 ± 4.7 14 7.8 ± 2.9 13 2.7 ± 1.2 9 2.2 ± 0.73 0.33 0.57 0.89 
LH (IU/L) 11 4.5 ± 0.75 13 6.5 ± 2.1 12 7.2 ± 2.92 11 7.4 ± 1.9 0.94 0.93 0.74 
FSH (IU/L) 11 4.9 ± 0.54 14 4.9 ± 1.01 12 5.03 ± 1.2 11 6.7 ± 1.08 0.49 0.86 0.25 
Values are expressed as mean ± SE. Values adjusted for age. #, BMI effect; and *, ethnic effect.  SI, sensitivity index; HOMAIR, homeostasis model for insulin 

































































































Figure 3: Expression of genes in abdominal DSAT, SSAT and gluteal  depots in normal-weight and obese black and white women.  Bars represent mean ± SE. *, 
P<0.05, Black vs. white; #, P<0.05, normal-weight vs. obese. ERα, oestrogen receptor alpha; ERβ, oestrogen  receptor beta; CYP19A, aromatase, NWB; normal-
weight black, NWW; normal weight white, OB; obese black and OW; obese white. 
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3.3.1 Subject characteristics 
Subject characteristics as described previously (50 and 146) are shown in Table 7. Obese women 
were older than normal weight women, and obese white women were older than obese black 
women. There was no significant difference in hormonal contraception use between black and 
white women (35% vs. 26%, respectively p=0.09) however, more white women used oral 
contraceptives (22% vs. 0%), whereas more black women used injectable contraceptives (36% 
vs. 4%, p<0.01).  
After adjusting for age, black and white women were well matched for BMI, body fat, FMI and 
WC and HC. When expressed relative to total body FM, normal-weight black women had less 
trunk FM (%) and absolute trunk FM (kg) compared to their white counterparts. With obesity, 
trunk FM and trunk FM/leg FM increased and leg FM decreased to a greater extent in the black 
compared to the white women. VAT did not differ in normal-weight women, but was 
significantly greater in obese white compared to obese black women. All measures of body fat 
were greater in obese compared to normal weight women in both groups.  
Fasting plasma glucose concentrations did not differ by ethnicity, but were significantly higher in 
obese white women compared to normal-weight white women. Fasting serum insulin 
concentrations and HOMAIR were higher in the obese black compared to obese white women. SI 
was significantly lower in black women compared to white women in both BMI groups. SI was 
lower, and fasting serum insulin concentrations and HOMAIR were higher in obese compared to 
normal-weight women in both ethnic groups. 
Differences in circulating sex hormones between the normal-weight and obese black and white 
women are presented in Table 8. E2 concentrations did not differ between normal-weight black 
and white women, but were lower in the obese white, but not the black women. Testosterone 
concentrations were significantly lower in black compared to the white women in both BMI 
groups. Testosterone concentrations did not differ by BMI in black women, but normal-weight 
white women had significantly lower testosterone concentrations compared to obese white 
women. SHBG concentrations did not differ by ethnicity, but normal-weight black women had 
significantly greater SHBG concentrations compared to obese black women. When adjusting for 
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contraception use, the BMI and ethnic differences in hormone concentrations described above 
still remained significant (data not shown). 
3.3.2 SAT gene expression  
The expression of ER‟s and aromatase in DSAT, SSAT and gluteal SAT are shown in figure 3. 
In the gluteal depot only, ERα was significantly higher and ERβ was significantly lower in the 
black compared to white women in both BMI groups. Accordingly, gluteal ERα/ERβ was 
significantly higher in the black compared to the white women in both BMI groups. Further 
gluteal ERα was significantly lower in obese white compared to normal-weight white women. 
There were no ethnic or BMI differences in the expression of ER‟s in the SSAT or DSAT depots. 
CYP19A expression was higher in the obese compared to the normal-weight black and white 
women in all three depots. There were no ethnic differences in aromatase expression in any of 
the depots.  
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Figure 4: Associations between ERα, ERβ, ERα/ERβ (figure 4A) and CYP19A (figure 4B) gene 
expression with body fat and its distribution in gluteal, SSAT and DSAT depots in black and white 
women. FMI, fat mass index; TFM, trunk fat mass; e x gene, ethnicity x gene interaction. 
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Figure 5: Associations between ERα and ERβ gene expression with metabolic risk in gluteal and SSAT 
depots. HOMAIR, homeostasis model of insulin resistance; e x gene, ethnicity x gene interaction. 
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3.3.3 Associations between gene expression and body fat and its distribution and IR. 
When examining the associations between gene expression and total body fatness, lower gluteal 
ERα expression was associated with higher FMI in the white women only (Figure 4A).  Further, 
there was a significant ERα/ERβ (in both the gluteal and SSAT depots) x ethnicity interaction for 
FMI, such that reduced ERα/ERβ expression was associated with higher FMI in the white, but 
not black women (Figure 4A). Higher CYP19A was associated with higher FMI in both black 
and white women in all 3 depots (Figure 4B). After adjusting for age and FMI, there was 
significant gluteal ERα x ethnicity interaction for trunk FM, such that lower ERα was associated 
with higher trunk FM in the black, but not white women (Figure 4A). Adipose tissue gene 
expression was not associated with leg FM and gynoid FM in black or white women. 
After adjusting for age and FMI, increased gluteal ERα expression was associated with lower 
fasting insulin (r=-0.53, p=0.01) and HOMAIR in the black women only (Figure 5). Conversely, 
higher ERβ expression in the SSAT depot was associated with higher HOMAIR in the black 
women (Figure 5). The associations between gene expression and body composition and IR were 
not altered when further adjusting for contraception use. 
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Figure 6: Associations between circulating sex hormones with body fat and IR. FMI, fat mass index, TST, testosterone; SHBG, sex hormone binding globulin; SI, 
sensitivity index; e x circulating hormone, ethnicity x circulating hormone interaction. 
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3.3.4 Associations between circulating hormonal levels and body fat and its distribution 
and IR  
When adjusting for age and FMI, there were significant interactions between ethnicity x 
hormone concentrations for FMI. Higher testosterone concentrations were associated with higher 
FMI in the white, but not black women. In contrast, reduced SHBG concentrations were 
associated with higher FMI in black, but not white women. After adjusting for age and FMI, 
higher SHBG was associated with lower fasting insulin concentrations in the white women only, 
and when also adjusting for contraception use, higher SHBG concentrations were significantly 
associated with higher SI in the white women (r=0.59, p=0.03). Adjustment for contraceptive use 
did not alter any other finding reported above. There were no associations with FSH, LH or E2 




The main findings of this study were that gluteal expression of ERα was significantly greater and 
ERβ was significantly lower in the black compared to the white women. Accordingly, gluteal 
ERα/ERβ expression was higher in the black compared to the white women.  Notably, in black 
women only, increased gluteal ERα expression was associated with lower central FM and lower 
fasting serum insulin concentrations and HOMAIR. While adipose tissue ER gene expression did 
not associate with body fat distribution or IR in white women, free testosterone levels were 
higher in white compared to black women, and correlated with adiposity in white women only. 
In contrast, circulating SHBG concentrations were negatively associated with adiposity in the 
black women, and negatively associated with fasting insulin concentrations and IR in white 
women after additionally adjusting for contraception use.  
Compared to white women, black women had increased ERα and ERα/ERβ in the gluteal depot, 
but not the abdominal SAT depot. To our knowledge this is the first study to show differences in 
gluteal mRNA expression of ER‟s in black and white women. In white women only, lower ERα 
and ERα/ERβ expression in both the SSAT and gluteal depots were associated with increased 
adiposity. These findings are supported by studies in ERKO mice which show an obese 
phenotype (201-204), as well as a study conducted in European women, which demonstrated that 
SAT expression of ERα was lower in obese compared to normal-weight women (200).  
In black women, gluteal ERα expression was associated with lower central FM. These findings 
are commensurate with studies that have suggested that increased ER‟s are associated with 
increased peripheral FM (229). Further, murine studies have demonstrated that a decrease in ERα 
expression results in an increase in VAT (201-204). This may therefore suggest that oestrogen 
receptor gene expression may be associated with the lower abdominal obesity in the black 
women. The reasons for these ethnic-specific associations are not known. Further studies, 
including longitudinal studies are required to examine this to determine possible reasons.  
Increased ERα and decreased ERβ expression was associated with improved IR in the black, but 
not white women. Mice studies have demonstrated that an increase in ERα is associated with a 
decrease in IR and decrease in body fat (201-204). In BERKO mice, improvement in IR was 
demonstrated despite an increase in body fat (207). Studies have also shown higher SAT 
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expression of ERβ in postmenopausal women compared to premenopausal women (255). Despite 
higher ERα and lower ERβ in black compared to white women, and the association with lower 
IR, black women in this study were more IR than their white counterparts, as determined by 
fasting insulin concentrations and the FSIGT-derived measure. However, higher ERα and lower 
ERβ expression in the black women only associated with lower fasting measures of IR 
(HOMAIR and fasting insulin concentrations), which more likely reflect hepatic IR. We have 
recently shown that compared to white women, black women have lower hepatic, but similar 
peripheral IR (Goedecke et al, in review).  Further, other studies have shown that the prevalence 
of hepatic steatosis (liver fat) is lower in the black compared to the white women (107). A study 
conducted in ERKO mice demonstrated by the euglycaemic hyperinsulinaemic clamp, that the 
normal insulin mediated suppression of glucose was blunted which revealed a pronounced 
hepatic IR (202). This may therefore suggest that ER‟s may be associated with lower hepatic IR 
in the black women. 
Mechanisms that may possibly link ER expression, obesity and IR may include the expression of 
other genes. For example, studies have shown that ERβ inhibits PPARϒ activity (207) which 
regulates glucose and lipid metabolism by modulating energy homeostasis in adipose tissue and 
skeletal muscle (208-210). Consistently low PPARϒ activity leads to IR, diabetes and end organ 
damage (208). However, Goedecke et al (2011) previously demonstrated that PPARϒ was down-
regulated to a greater extent with obesity in black women compared to white women, and 
associated negatively with IR in the black and not the white women (50). In contrast, Bower et al 
(2006) demonstrated no difference in mRNA expression of PPARϒ in obese black compared to 
obese white women (259). Due to contradictory findings, further studies examining the 
association between ER‟s and PPARϒ should be conducted. Further, diarylpropiolnitrile (DPN), 
an agonist for ERβ, was used to demonstrate that oestrogens acting via ERβ may also increase 
adiposity due to upregulation of 11βHSD1, which is increased in obese humans and mice models 
of obesity, through an ERβ agonist (255). Another possible mechanism involves the increase in 
the expression of genes involved in lipid biosynthesis, such as SCD1, reported in ERKO mice 
(202). These genes have been shown to be associated with obesity and IR (213 and 214). Studies 
have demonstrated that SCD1 is reduced in African American compared to Caucasian women.  




When comparing circulating steroid levels, lower E2 levels were observed in obese compared to 
normal-weight white but not black women. Although incongruous with adipose tissue ERα 
expression, the findings in white women are supported by studies that show that ovariectomy 
results in an increase in BMI, VAT and central FM (168-173). A possible mechanism through 
which circulating E2 causes reduced obesity is that oestrogen may exert effects on several 
adipokines that are produced by adipocytes. Oestrogen levels in premenopausal women have 
been shown to be closely associated with leptin levels (175 and 176). Additionally in mice, 
oestrogen has been shown to reduce leptin resistance (177), by controlling the expression of 
leptin specific receptors (176, 178 and 179). Studies have demonstrated that although circulating 
leptin levels were higher in obese black compared to obese white women, leptin concentrations 
were more strongly correlated with obesity indices in the white women (260) suggesting a 
possible reason for the association of E2 concentrations with obesity in the white and not black 
women. 
We also found that testosterone concentrations were lower in black compared to white women, 
irrespective of BMI group, and were associated with greater adiposity in the white women only. 
Studies conducted in premenopausal women demonstrated that testosterone levels were 
positively correlated with body FM (kg and %) in women aged 20-25 years (192). It has been 
suggested that the levels of free testosterone may be elevated because of low androgen binding to 
SHBG, which associates with obesity (184). We found that although SHBG concentrations were 
not significantly different in black and white women, which is consistent with other studies 
(194), SHBG concentrations were negatively associated with adiposity in the black women only. 
This is in accordance with studies conducted in premenopausal African American women who 
demonstrated significant negative correlations between obesity and SHBG (187). However, this 
is in contrast to a study conducted in a larger sample size which demonstrated that although 
SHBG levels were similar in black and white women, total adiposity was associated with SHBG 
in the white women only (194). This is interesting as testosterone levels were lower in the black 
compared to the white women and it would be expected that SHBG would therefore be higher in 
the black women, suggesting that other factors such as contraception use may affect the levels of 
SHBG in the black women. Studies have demonstrated that oral contraception use increases 
SHBG levels (261). However, our results remained the same after taking into account 
contraception use of the black and white women. Other factors such as growth hormone have 
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also been shown to affect SHBG levels, and should therefore be measured in future studies 
(262). Additionally, we found that SHBG, independent of age, FMI and contraception use was 
negatively associated with IR in white women. Studies conducted in Caucasian women 
demonstrated that low SHBG levels were associated with IR (188 and 189). The reason for 
SHBG association with IR in the white and not black women is not known, but, could possibly 
be due to racial differences in sex steroid metabolism and the regulation of their cellular and 
physiological actions. Studies providing evidence on the specific regulation of their cellular and 
physiological actions should be undertaken. Therefore, the implications of this study are that 
higher androgenicity, due to increased testosterone may be a phenotype that is associated with 
obesity in white women. In contrast, SHBG may be associated with obesity in the black women 
and IR in the white women.  
Oestrogen production is dependent on CYP19A activity in adipose tissue, which converts 
androstenedione to oestrone followed by the conversion to oestrogen (167). CYP19A increased 
with obesity and was positively associated with increased adiposity in both black and white 
women in all depots. This finding is supported by other studies conducted in men and 
premenopausal women which demonstrated that generalized obesity characterised by BMI was 
associated with an increase in CYP19A expression (229). It has been suggested that the 
mechanism by which CYP19A increases fat deposition is by consuming more androgen ligands 
and generating more oestrogen ligands which favours peripheral fat deposition and may cause 
raised plasma oestrogen levels (229). However, in our study we did not show raised plasma 
oestrogen levels with obesity, but rather reduced oestrogen levels with obesity in the white 
women. Additionally there was no association with body fat distribution as it would be expected 
that lower plasma oestrogen levels would be associated with reduced peripheral FM. Differences 
in findings could be due to differences in sample size as our study had a higher sample size 
compared to the study mentioned above. These findings are therefore contradictory and further 
studies are required to verify these results.  
The strengths of this study include the precise measures of body fat distribution (i.e. DXA and 
CT) on a cohort of normal-weight and obese women who differed in body composition and IR. 
The cross-sectional design of this study limits one to derive conclusions in terms of causality, 
and the study is limited by a small sample size. However, no studies of which we are of aware 
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have compared the associations of sex hormones and body fat distribution and IR between black 
and white SA women. Larger samples are required to verify the relationships and determine 
whether these associations are ethnic-specific.  We did not obtain fat biopsies or measure IR 
during the same menstrual cycle phase for each subject and this may affect the oestrogen 
receptor levels and circulating hormonal levels and the associations with body composition and 
IR. Further, different methods of contraception in the black and white women may have affected 
the results. Contraception use is known to alter body composition, IR and sex hormones, 
however, we found that when adjusting for contraception use the relationships did not change. 
This study only measured mRNA levels and measurements of protein levels are needed to verify 
the findings of this study. 
In conclusion, these results show ethnic differences in body fat distribution were associated with 
regional differences in expression of ER‟s. Although differences in oestrogen expression were 
associated with IR in the black women, further studies are required to explore other factors 
affecting peripheral IR in black women. In addition, CYP19A was associated with overall 
obesity in both the black and white women. This study also showed differences in circulating sex 
hormones, which associated with total body fat but not distribution. These results support the 
fundamental differences in the effects of sex hormones on metabolism and body composition in 
black and white women. Understanding the mechanisms by which sex hormones affect IR could 
have important preventative health implications. Based on these findings, future longitudinal 
studies, including a larger sample size in which menstrual cycle and contraception use are 
controlled, are required to verify these findings to provide further insight into strategies to 






Summary and conclusions 
 
Within SA, the prevalence of overweight and obesity is high, especially in women, with black 
SA women most affected (7). Obesity, and in particular central obesity, is closely associated with 
increased risk of developing T2D and CVD (24-26). In contrast, peripheral FM has been shown 
to be protective against cardio-metabolic risk (24, 38 and 39). Studies have demonstrated that 
black women have greater peripheral FM but lower VAT compared to their white counterparts 
(46-52, 72, 75, 81 and 82). Nonetheless, black SA women have a high prevalence of IR and 
T2D, whereas white SA women have a higher risk of dyslipidaemia and CVD (53-56 and 58). 
Previous research has demonstrated ethnic differences in the relationship between body fat 
distribution and metabolic risk in black and white women. To date, the SA studies that have 
examined the ethnic-specific associations between body composition and cardio-metabolic risk 
among black and white women have only used anthropometric-derived measures of body 
composition (BMI and WC) (76 and 82), or in small samples of women, specifically examined 
the associations between VAT and SAT, measured using CT (49-55). To our knowledge, no 
studies have examined the ethnic differences in whole body fat distribution using DXA, the gold 
standard measure of whole body composition, and explored the independent associations 
between central vs. peripheral fat distribution and cardio-metabolic risk in black and white SA 
women. Body fat distribution is intricately linked to sex hormones, a case in point being the 
centralisation of body fat following menopause (158-164). Differences in sex hormones and their 
receptors and the ethnic-specific associations with body fat and IR have not been explored in SA. 
Therefore, a need to explore differences in sex hormones, which could possibly explain 
differences in body fat distribution and thus its implications in terms of IR is important.  
Therefore the aims of this thesis were to i) examine the ethnic-specific association between body 
fat distribution and cardio-metabolic risk; and ii) examine the associations between circulating 
sex hormones and the expression of their receptors in adipose tissue and body fat distribution and 
IR among black and white SA women. 
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In addressing the first aim, we found that in the first study of this thesis, black women were 
shorter and had greater FM compared to white women; accordingly, all analyses were adjusted 
for FMI. A major finding of the first study was that compared to white women, black women had 
lower central FM, characterised by lower trunk FM and greater lower-body FM, characterised by 
higher leg FM. In addition black women had lower VAT and greater abdominal SAT compared 
to white women. Despite lower central and greater lower-body fat, black women had similar 
levels of IR based on fasting insulin and HOMAIR, but had lower glucose levels compared to 
their white counterparts. Commensurate with previous findings, black women had lower lipid 
levels compared to white women. In white women only, elevated TC and LDL-C concentrations 
were associated with their greater central FM, whereas in black women only, lower central FM 
was associated with lower fasting glucose levels. This suggests that central FM may play a vital 
role in determining glucose concentrations and hence the risk for T2D in black women and 
serum lipids, and risk for CVD in white women.  
In contrast to the findings for glucose and lipid levels, greater central and reduced lower-body 
FM were similarly associated with higher IR, as well as higher TG and lower HDL-C 
concentrations in the black and white women. Additionally, central and lower-body fat were 
independently associated with IR in both black and white women. These findings suggest that 
other factors, in addition to body fat are important determinants of IR and HDL-C concentrations 
in black women. Accordingly we showed that some of these factors include contraceptive use, 
physical activity and alcohol consumption. In the black women, injectable contraceptive use was 
associated with increased IR and reduced HDL-C, whereas in white women, oral contraception 
use was positively associated with HDL-C concentrations. Further, alcohol consumption in the 
black women was positively associated with HDL-C concentrations. In addition in white women 
only, MVPA was associated with reduced IR.  
In the SA context, lifestyle factors such as contraception use and physical activity are influenced 
by socio-economic factors. Studies have shown that majority of women living in informal 
settlements used injectable contraception, which was a method determined by their health care 
provider (263 and 264). Additionally, although we showed that MVPA was higher in the black 
compared to white women, MVPA was only a significant correlate of IR in white women. 
However, previous research from our laboratory showed that black women mainly perform 
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physical activity for travel purposes, which are typically undertaken at a relatively low intensity, 
whereas white women perform physical activity for leisure, typically undertaken at a higher 
intensity. Based on these findings, intervention studies aimed at reducing centralisation of body 
fat, increasing higher intensity physical activity and changing contraceptive use are required to 
provide evidence-based guidelines for the prevention and management of cardio-metabolic risk.  
Based on the findings of greater central and reduced lower-body fat in the white compared to the 
black women, we explored the associations between circulating sex hormones and their receptors 
in deep, superficial and gluteal adipose tissue and body fat and its distribution and IR. The major 
and novel finding of this study was that gluteal ERα was higher and ERβ was lower in the black 
compared to the white women, and that in black women only, increased gluteal ERα expression 
was associated with their lower central FM. This suggests that ER gene expression may be 
associated with lower abdominal fat demonstrated in the black women. Reasons for alterations in 
gene expression are unknown, but could possibly be due to genetic factors, which include genes 
such as SCD1, which has been shown to increase in ERKO mice (202). Further environmental 
factors such as, application of cosmetics containing p-hydroxybenzoic acid ester have recently 
been shown to be oestrogenic and has been found in human breast tissue, indicating absorption 
(265). The levels of oestrogen in the body may in turn affect ER expression. Thus the effects of 
environmental factors on ER expression should be explored in future studies. Additionally, in the 
black women, increased ERα and decreased ERβ were associated with lower IR. Despite higher 
ERα and lower ERβ in black compared to white women, and the association with lower IR, black 
women in this study were more IR than their white counterparts, as determined by fasting insulin 
concentrations and the FSIGT-derived measure, SI. However, higher ERα and lower ERβ 
expression in the black women only associated with lower fasting measures of IR (HOMAIR and 
fasting insulin concentrations), which more likely reflect hepatic IR. This may therefore suggest 
that ER may be associated with lower hepatic IR in the black women.  
In the white women, ERα was reduced in obese compared to normal-weight women and was 
associated with adiposity. Although incongruous with adipose ERα expression, lower circulating 
E2 levels were observed in obese compared to normal-weight women. E2 production is 
dependent on CYP19A activity in adipose tissue (167). We showed that CYP19A was associated 
with overall obesity in both the black and white women, suggesting that higher CYP19A may 
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play a pivotal role in determining overall obesity in the black and white women. We also found 
that, circulating free testosterone levels were higher in white compared to black women, and 
correlated with adiposity in white women only. There was no significant difference in SHBG 
levels between black and white women. However, in the white women only, SHBG was 
negatively associated with IR, independent of age, FMI and contraception use. In contrast, in the 
black women only, SHBG was negatively associated with adiposity. The complexity of differing 
associations between SHBG and adiposity and IR in the black and white women, in light of 
testosterone may therefore imply that other factors may affect their SHBG levels. This therefore 
implies that higher androgenicity as reflected by increased testosterone may be a phenotype that 
is associated with obesity in white women, whereas SHBG may be associated with IR in the 
white women, and obesity in the black women.  
These results support the fundamental differences in the effects of sex hormones on metabolism 
and body composition in black and white women. Understanding the mechanisms by which sex 
hormones affect IR could have important preventative health implications. Based on these 
findings, longitudinal studies should be conducted in a larger sample size. Further, as menstrual 
cycle was not controlled for, future studies should consider this to verify these findings for 
further insight into strategies to prevent and manage cardio-metabolic risk. 
The strengths of this study include the state-of-the-art measures of body fat distribution, DXA 
and CT, and the examination of ethnic-specific associations between these measures and cardio-
metabolic risk. In addition, no studies of which we are of aware have compared the associations 
of sex hormones and their receptors in adipose tissue and body fat distribution and IR between 
black and white SA women. 
Possible limitations of the study were the inclusion of a convenient sample of women, which is 
not representative of total population. Black women were more obese that white women but this 
maybe reflective of the population according to SANHANES (7). The cross-sectional design of 
the study limits one to derive conclusions in terms of causality. For study 1, the number of 
women in which CT scans were conducted was low (76% of total sample) and this may have 
created type II error. Further, we did not measure other lifestyle factors such as diet and this has 
been shown to affect body fat and metabolic risk. More objective measures of physical activity 
using accelerometers should be used as it would give more insight into possible differences in 
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non-exercise thermogenesis within these populations and should therefore be conducted in future 
studies. Future studies should also include subjects with a wider age range and metabolic risk 
factors could differ with age. We did not obtain fat biopsies or measure IR during the same phase 
of menstrual cycle for each subject, and this may affect the ER and circulating hormonal levels 
and consequently, the associations with body composition and IR. A major limitation of the 
study was that during subject recruitment data regarding the phase of menstrual cycle was not 
collected. We do understand that menstrual cycle phase plays an important role in sex hormone 
levels and is therefore a major limitation of the study, and should be considered in future studies. 
This study only measured mRNA levels and measurements of protein levels are needed to verify 
the findings. Further, different methods of contraception in the black and white women may have 
affected the results. Contraception use in this study is reflective of what is used at the population 
level (264). However, we found that when adjusting for contraception use the relationships did 
not change.  
In conclusion, this study showed that central FM may be associated with their glucose levels in 
the black women and TC and LDL-C levels in the white women. The first novel finding of study 
1 was that central and lower-body FM were independently associated with IR in both the black 
and white women. In addition, modifiable risk factors, including MVPA and contraception use 
were associated with cardio-metabolic risk and can be used as therapeutic targets to prevent and 
manage cardio-metabolic disease risk. The second novel finding of this study was that ethnic 
differences in body fat distribution were associated with regional differences in expression of 
ER‟s in gluteal depot of adipose tissue. Although we showed that differences in oestrogen 
expression were associated with IR in gluteal and SSAT depot in the black women, further 
studies are required to explore other factors affecting peripheral IR in black women. In addition, 
circulating sex hormones were associated with total body fat but not distribution. To our 
knowledge this is the first study to examine the roles of sex hormones in body fat distribution 
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Table 9: Metabolic outcomes between contraception use in black and white women 
  No contraception use   Contraception use   P-value 
  N Median (IQR) N Median (IQR)   
Black 
     Glucose (mmol/L) 182 4.5 (4.2-4.9) 91 4.6 (4.2-5.0) 0.6 
Insulin (mU/L) 189 9.0 (5.3-15.8) 92 11.7 (6.8-17.4) 0.03 
HOMAIR 182 1.8 (1-3.2) 91 2.3 (1.3-3.7) 0.04 
TC (mmol/L) 180 3.9 (3.4-4.6) 87 3.7 (3.2-4.3) 0.8 
TG (mmol/L) 180 0.67 (0.5-1.0) 87 0.7 (0.5-0.9) 0.3 
HDL-C (mmol/L) 180 1.3 (1.1-1.6) 86 1.1 (0.9-1.4) <0.01 
LDL-C (mmol/L) 180 2.2 (1.7-2.7) 86 2.3 (1.6-2.8) 0.7 
White           
Glucose (mmol/L) 133 4.7 (4.5-4.9) 61 4.6 (4.3-4.9) 0.07 
Insulin (mU/L) 134 6.4 (4.6-11.09) 61 8.2 (5.3-10.6) 0.8 
HOMAIR 133 1.3 (0.95-2.3) 61 1.6 (1.04-2.1) 0.9 
TC (mmol/L) 134 4.5 (4.1-5.2) 61 5 (4.5-5.5) 0.01 
TG (mmol/L) 134 0.8 (0.6-1.2) 61 1 (0.7-1.4) <0.01 
HDL-C (mmol/L) 134 1.5 (1.3-1.8) 61 1.7 (1.5-2) <0.01 
LDL-C (mmol/L) 134 2.5 (2.1-3.2) 61 2.7 (2.2-3.4) 0.3 
Values are presented as median and interquartile range (IQR). HOMAIR, homeostasis model of insulin resistance; TC, total cholesterol; TG, trigylcerides; HDL-C, 
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol 
 
Table 10: Associations between physical activity and alcohol consumption and metabolic outcomes 









MVPA mins/week B -0.003 -0.05 -0.08 -0.09 -0.08 -0.07 -0.03 
  W 0.05 -0.19* -0.18* -0.02 -0.07 0.004 -0.09 
Alcohol consumption (g) B 0.12 -0.03 -0.02 0.06 -0.01 0.20* -0.07 
  W 0.05 -0.05 -0.05 0.05 -0.02 0.16 -0.13 
Values are presented as correlation coefficients. *, p<0.05. MVPA, moderate-vigourous physical activity; HOMAIR, homeostasis model of insulin resistance; TG, 
trigylcerides; TC, total cholesterol; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol. 
